Transcription regulation of the human telomerase reverse transcriptase (hTERT) gene

Genes

Volumn 7, Issue 8, 2016, Pages

  Ramlee, Muhammad Khairul ^a   Wang, Jing ^a   Toh, Wei Xun ^a   Li, Shang ^a,b  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Mutation; Promoter; Telomerase; Telomere; Transcription regulation

Indexed keywords

COLECALCIFEROL RECEPTOR; EARLY GROWTH RESPONSE FACTOR 1; ESTROGEN RECEPTOR; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KRUPPEL LIKE FACTOR 2; KRUPPEL LIKE FACTOR 4; MYC PROTEIN; PROTEIN MAD1; STAT3 PROTEIN; STAT5 PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR CTCF; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR NFX1; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR PAX8; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; UNCLASSIFIED DRUG; UPSTREAM STIMULATORY FACTOR 1; UPSTREAM STIMULATORY FACTOR 2;

3' UNTRANSLATED REGION; BINDING SITE; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; CHROMOSOME REARRANGEMENT; DNA METHYLATION; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE LOCATION; GENE MUTATION; GENE REGULATORY NETWORK; HISTONE MODIFICATION; HTERT GENE; HUMAN; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; RNA STABILITY; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 84983343511     PISSN: None     EISSN: 20734425     Source Type: Journal    
DOI: 10.3390/genes7080050     Document Type: Review

References (355)

1. Blackburn, E.H. Telomere states and cell fates. Nature 2000, 408, 53-56. [CrossRef] [PubMed]
2. De Lange, T. How shelterin solves the telomere end-protection problem. Cold Spring Harb. Symp. Quant. Biol. 2010, 75, 167-177. [CrossRef] [PubMed]
3. Makarov, V.L.; Hirose, Y.; Langmore, J.P. Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. Cell 1997, 88, 657-666. [CrossRef]
4. Wright, W.E.; Tesmer, V.M.; Huffman, K.E.; Levene, S.D.; Shay, J.W. Normal human chromosomes have long G-rich telomeric overhangs at one end. Genes Dev. 1997, 11, 2801-2809. [CrossRef] [PubMed]
5. Feng, J.; Funk, W.D.; Wang, S.S.; Weinrich, S.L.; Avilion, A.A.; Chiu, C.P.; Adams, R.R.; Chang, E.; Allsopp, R.C.; Yu, J. et al. The RNA component of human telomerase. Science 1995, 269, 1236-1241. [CrossRef] [PubMed]
6. Nakamura, T.M.; Morin, G.B.; Chapman, K.B.; Weinrich, S.L.; Andrews, W.H.; Lingner, J.; Harley, C.B.; Cech, T.R. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997, 277, 955-959. [CrossRef] [PubMed]
7. Kim, N.W.; Piatyszek, M.A.; Prowse, K.R.; Harley, C.B.; West, M.D.; Ho, P.L.; Coviello, G.M.; Wright, W.E.; Weinrich, S.L.; Shay, J.W. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266, 2011-2015. [CrossRef] [PubMed]
8. Masutomi, K.; Yu, E.Y.; Khurts, S.; Ben-Porath, I.; Currier, J.L.; Metz, G.B.; Brooks, M.W.; Kaneko, S.; Murakami, S.; DeCaprio, J.A. et al. Telomerase maintains telomere structure in normal human cells. Cell 2003, 114, 241-253. [CrossRef]
9. Wright, W.E.; Piatyszek, M.A.; Rainey, W.E.; Byrd, W.; Shay, J.W. Telomerase activity in human germline and embryonic tissues and cells. Dev. Genet. 1996, 18, 173-179. [CrossRef]
10. Levy, M.Z.; Allsopp, R.C.; Futcher, A.B.; Greider, C.W.; Harley, C.B. Telomere end-replication problem and cell aging. J. Mol. Biol. 1992, 225, 951-960. [CrossRef]
11. De Lange, T.; Lundblad, V.; Blackburn, E.H. Telomeres, 2nd ed.; Cold Spring Harbor Laboratory Press: Plainview, NY, USA, 2005; p. 576.
12. Harley, C.B.; Futcher, A.B.; Greider, C.W. Telomeres shorten during ageing of human fibroblasts. Nature 1990, 345, 458-460. [CrossRef] [PubMed]
13. Takai, H.; Smogorzewska, A.; de Lange, T. DNA damage foci at dysfunctional telomeres. Curr. Biol. 2003, 13, 1549-1556. [CrossRef]
14. dAdda di Fagagna, F.; Reaper, P.M.; Clay-Farrace, L.; Fiegler, H.; Carr, P.; Von Zglinicki, T.; Saretzki, G.; Carter, N.P.; Jackson, S.P. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003, 426, 194-198. [CrossRef] [PubMed]
15. Kaul, Z.; Cesare, A.J.; Huschtscha, L.I.; Neumann, A.A.; Reddel, R.R. Five dysfunctional telomeres predict onset of senescence in human cells. EMBO Rep. 2012, 13, 52-59. [CrossRef] [PubMed]
16. Hayflick, L.; Moorhead, P.S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 1961, 25, 585-621. [CrossRef]
17. Flores, I.; Canela, A.; Vera, E.; Tejera, A.; Cotsarelis, G.; Blasco, M.A. The longest telomeres: A general signature of adult stem cell compartments. Genes Dev. 2008, 22, 654-667. [CrossRef] [PubMed]
18. Artandi, S.E.; DePinho, R.A. Telomeres and telomerase in cancer. Carcinogenesis 2010, 31, 9-18. [CrossRef] [PubMed]
19. Schaetzlein, S.; Lucas-Hahn, A.; Lemme, E.; Kues, W.A.; Dorsch, M.; Manns, M.P.; Niemann, H.; Rudolph, K.L. Telomere length is reset during early mammalian embryogenesis. Proc. Natl. Acad. Sci. USA 2004, 101, 8034-8038. [CrossRef] [PubMed]
20. Holohan, B.; Wright, W.E.; Shay, J.W. Cell biology of disease: Telomeropathies: An emerging spectrum disorder. J. Cell Biol. 2014, 205, 289-299. [CrossRef] [PubMed]
21. Armanios, M.; Blackburn, E.H. The telomere syndromes. Nat. Rev. Genet. 2012, 13, 693-704. [CrossRef] [PubMed]
22. Lansdorp, P.M. Telomeres and disease. EMBO J. 2009, 28, 2532-2540. [CrossRef] [PubMed]
23. Blasco, M.A.; Lee, H.W.; Hande, M.P.; Samper, E.; Lansdorp, P.M.; DePinho, R.A.; Greider, C.W. Telomere shortening and tumor formation by mouse cells lacking telomerase rna. Cell 1997, 91, 25-34. [CrossRef]
24. Lee, H.W.; Blasco, M.A.; Gottlieb, G.J.; Horner, J.W., II; Greider, C.W.; DePinho, R.A. Essential role of mouse telomerase in highly proliferative organs. Nature 1998, 392, 569-574. [PubMed]
25. Chou, W.C.; Chen, H.Y.; Yu, S.L.; Cheng, L.; Yang, P.C.; Dang, C.V. Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood 2005, 106, 304-310. [CrossRef] [PubMed]
26. Shay, J.W.; Bacchetti, S. A survey of telomerase activity in human cancer. Eur. J. Cancer 1997, 33, 787-791. [CrossRef]
27. Smith, L.L.; Coller, H.A.; Roberts, J.M. Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat. Cell Biol. 2003, 5, 474-479. [CrossRef] [PubMed]
28. Cong, Y.S.; Wen, J.; Bacchetti, S. The human telomerase catalytic subunit hTERT: Organization of the gene and characterization of the promoter. Hum. Mol. Genet. 1999, 8, 137-142. [CrossRef] [PubMed]
29. Horikawa, I.; Cable, P.L.; Afshari, C.; Barrett, J.C. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res. 1999, 59, 826-830. [PubMed]
30. Takakura, M.; Kyo, S.; Kanaya, T.; Hirano, H.; Takeda, J.; Yutsudo, M.; Inoue, M. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res. 1999, 59, 551-557. [PubMed]
31. Takahashi, K.; Tanabe, K.; Ohnuki, M.; Narita, M.; Ichisaka, T.; Tomoda, K.; Yamanaka, S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131, 861-872. [CrossRef] [PubMed]
32. Yu, J.; Vodyanik, M.A.; Smuga-Otto, K.; Antosiewicz-Bourget, J.; Frane, J.L.; Tian, S.; Nie, J.; Jonsdottir, G.A.; Ruotti, V.; Stewart, R. et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318, 1917-1920. [CrossRef] [PubMed]
33. Moehren, U.; Papaioannou, M.; Reeb, C.A.; Grasselli, A.; Nanni, S.; Asim, M.; Roell, D.; Prade, I.; Farsetti, A.; Baniahmad, A. Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: A novel role of AR mutation for prostate cancer development. FASEB J. 2008, 22, 1258-1267. [CrossRef] [PubMed]
34. Takakura, M.; Kyo, S.; Inoue, M.; Wright, W.E.; Shay, J.W. Function of AP-1 in transcription of the telomerase reverse transcriptase gene (TERT) in human and mouse cells. Mol. Cell. Biol. 2005, 25, 8037-8043. [CrossRef] [PubMed]
35. Sitaram, R.T.; Degerman, S.; Ljungberg, B.; Andersson, E.; Oji, Y.; Sugiyama, H.; Roos, G.; Li, A. Wilms' tumour 1 can suppress hTERT gene expression and telomerase activity in clear cell renal cell carcinoma via multiple pathways. Br. J. Cancer 2010, 103, 1255-1262. [CrossRef] [PubMed]
36. Kuhlmann, A.S.; Villaudy, J.; Gazzolo, L.; Castellazzi, M.; Mesnard, J.M.; Duc Dodon, M. HTLV-1 HBZ cooperates with jund to enhance transcription of the human telomerase reverse transcriptase gene (hTERT). Retrovirology 2007. [CrossRef] [PubMed]
37. Deng, W.G.; Jayachandran, G.; Wu, G.; Xu, K.; Roth, J.A.; Ji, L. Tumor-specific activation of human telomerase reverses transcriptase promoter activity by activating enhancer-binding Protein-2|3 in human lung cancer cells. J. Biol. Chem. 2007, 282, 26460-26470. [CrossRef] [PubMed]
38. Fu, L.; Chen, W.; Guo, W.; Wang, J.; Tian, Y.; Shi, D.; Zhang, X.; Qiu, H.; Xiao, X.; Kang, T. et al. Berberine targets AP-2/hTERT, NF-kB/COX-2, HIF-1a/VEGF and cytochrome-c/caspase signaling to suppress human cancer cell growth. PLoS ONE 2013, 8, e69240. [CrossRef] [PubMed]
39. Suryo Rahmanto, Y.; Jung, J.G.; Wu, R.C.; Kobayashi, Y.; Heaphy, C.M.; Meeker, A.K.; Wang, T.L.; Shih Ie, M. Inactivating arid1a tumor suppressor enhances TERT transcription and maintains telomere length in cancer cells. J. Biol. Chem. 2016, 291, 9690-9699. [CrossRef] [PubMed]
40. Hoffmeyer, K.; Raggioli, A.; Rudloff, S.; Anton, R.; Hierholzer, A.; Del Valle, I.; Hein, K.; Vogt, R.; Kemler, R. Wnt/p-catenin signaling regulates telomerase in stem cells and cancer cells. Science 2012, 336, 1549-1554. [CrossRef] [PubMed]
41. Zhang, Y.; Toh, L.; Lau, P.; Wang, X. Human telomerase reverse transcriptase (hTERT) is a novel target of the Wnt/| -catenin pathway in human cancer. J. Biol. Chem. 2012, 287, 32494-32511. [CrossRef] [PubMed]
42. Isenmann, S.; Cakouros, D.; Zannettino, A.; Shi, S.; Gronthos, S. hTERT transcription is repressed by Cbfa1 in human mesenchymal stem cell populations. J. Bone Miner. Res. 2007, 22, 897-906. [CrossRef] [PubMed]
43. Wu, K.J.; Grandori, C.; Amacker, M.; Simon-Vermot, N.; Polack, A.; Lingner, J.; Dalla-Favera, R. Direct activation of TERT transcription by c-Myc. Nat. Genet. 1999, 21, 220-224. [PubMed]
44. Xu, D.; Popov, N.; Hou, M.; Wang, Q.; Bjorkholm, M.; Gruber, A.; Menkel, A.R.; Henriksson, M. Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc. Natl. Acad. Sci. USA 2001, 98, 3826-3831. [CrossRef] [PubMed]
45. Ogretmen, B.; Kraveka, J.M.; Schady, D.; Usta, J.; Hannun, Y.A.; Obeid, L.M. Molecular mechanisms of ceramide-mediated telomerase inhibition in the a549 human lung adenocarcinoma cell line. J. Biol. Chem. 2001, 276, 32506-32514. [CrossRef] [PubMed]
46. Kyo, S.; Takakura, M.; Taira, T.; Kanaya, T.; Itoh, H.; Yutsudo, M.; Ariga, H.; Inoue, M. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res. 2000, 28, 669-677. [CrossRef] [PubMed]
47. Veldman, T.; Liu, X.; Yuan, H.; Schlegel, R. Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc. Natl. Acad. Sci. USA 2003, 100, 8211-8216. [CrossRef] [PubMed]
48. Gewin, L.; Myers, H.; Kiyono, T.; Galloway, D.A. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev. 2004, 18, 2269-2282. [CrossRef] [PubMed]
49. Faiola, F.; Liu, X.; Lo, S.; Pan, S.; Zhang, K.; Lymar, E.; Farina, A.; Martinez, E. Dual regulation of c-Myc by p300 via acetylation-dependent control of Myc protein turnover and coactivation of Myc-induced transcription. Mol. Cell. Biol. 2005, 25, 10220-10234. [CrossRef] [PubMed]
50. Wang, Y.W.; Chang, H.S.; Lin, C.H.; Yu, W.C. HPV-18 E7 conjugates to c-Myc and mediates its transcriptional activity. Int. J. Biochem. Cell Biol. 2007, 39, 402-412. [CrossRef] [PubMed]
51. Kyo, S.; Takakura, M.; Kanaya, T.; Zhuo, W.; Fujimoto, K.; Nishio, Y.; Orimo, A.; Inoue, M. Estrogen activates telomerase. Cancer Res. 1999, 59, 5917-5921. [PubMed]
52. Xu, D.; Dwyer, J.; Li, H.; Duan, W.; Liu, J.P. Ets2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-Myc. J. Biol. Chem. 2008, 283, 23567-23580. [CrossRef] [PubMed]
53. Oh, S.T.; Kyo, S.; Laimins, L.A. Telomerase activation by human papillomavirus type 16 E6 protein: Induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sites. J. Virol. 2001, 75, 5559-5566. [CrossRef] [PubMed]
54. McMurray, H.R.; McCance, D.J. Human papillomavirus type 16 E6 activates TERT gene transcription through induction of c-Myc and release of USF-mediated repression. J. Virol. 2003, 77, 9852-9861. [CrossRef] [PubMed]
55. Liu, X.; Dakic, A.; Zhang, Y.; Dai, Y.; Chen, R.; Schlegel, R. HPV E6 protein interacts physically and functionally with the cellular telomerase complex. Proc. Natl. Acad. Sci. USA 2009, 106, 18780-18785. [CrossRef] [PubMed]
56. Li, H.; Lee, T.H.; Avraham, H. A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer. J. Biol. Chem. 2002, 277, 20965-20973. [CrossRef] [PubMed]
57. Bu, D.X.; Johansson, M.E.; Ren, J.; Xu, D.W.; Johnson, F.B.; Edfeldt, K.; Yan, Z.Q. Nuclear factor {kappa}B-mediated transactivation of telomerase prevents intimal smooth muscle cell from replicative senescence during vascular repair. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 2604-2610. [CrossRef] [PubMed]
58. Sinha-Datta, U.; Horikawa, I.; Michishita, E.; Datta, A.; Sigler-Nicot, J.C.; Brown, M.; Kazanji, M.; Barrett, J.C.; Nicot, C. Transcriptional activation of hTERT through the NF-kB pathway in HTLV-I-transformed cells. Blood 2004, 104, 2523-2531. [CrossRef] [PubMed]
59. Yamashita, S.; Ogawa, K.; Ikei, T.; Fujiki, T.; Katakura, Y. FOXO3a potentiates hTERT gene expression by activating c-Myc and extends the replicative life-span of human fibroblast. PLoS ONE 2014, 9, e101864. [CrossRef] [PubMed]
60. Ponnala, S.; Chetty, C.; Veeravalli, K.K.; Dinh, D.H.; Klopfenstein, J.D.; Rao, J.S. MMP-9 silencing regulates hTERT expression via | 1 integrin-mediated FAK signaling and induces senescence in glioma xenograft cells. Cell Signal 2011, 23, 2065-2075. [CrossRef] [PubMed]
61. Yang, H.; Ou, C.C.; Feldman, R.I.; Nicosia, S.V.; Kruk, P.A.; Cheng, J.Q. Aurora-a kinase regulates telomerase activity through c-Myc in human ovarian and breast epithelial cells. Cancer Res. 2004, 64, 463-467. [CrossRef] [PubMed]
62. Yang, J.; Deng, X.; Deng, L.; Gu, H.; Fan, W.; Cao, Y. Telomerase activation by Epstein-Barr virus latent membrane protein 1 is associated with c-Myc expression in human nasopharyngeal epithelial cells. J. Exp. Clin. Cancer Res. 2004, 23, 495-506. [PubMed]
63. Endoh, T.; Tsuji, N.; Asanuma, K.; Yagihashi, A.; Watanabe, N. Survivin enhances telomerase activity via up-regulation of specificity protein 1- and c-Myc-mediated human telomerase reverse transcriptase gene transcription. Exp. Cell Res. 2005, 305, 300-311. [CrossRef] [PubMed]
64. Sheng, W.Y.; Chen, Y.R.; Wang, T.C. A major role of PKC 6 and NFkB in the regulation of hTERT in human T lymphocytes. FEBS Lett. 2006, 580, 6819-6824. [CrossRef] [PubMed]
65. Liu, C.; Fang, X.; Ge, Z.; Jalink, M.; Kyo, S.; Bjorkholm, M.; Gruber, A.; Sjoberg, J.; Xu, D. The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3. Cancer Res. 2007, 67, 2626-2631. [CrossRef] [PubMed]
66. Liu, X.; Vorontchikhina, M.; Wang, Y.L.; Faiola, F.; Martinez, E. Staga recruits mediator to the Myc oncoprotein to stimulate transcription and cell proliferation. Mol. Cell. Biol. 2008, 28, 108-121. [CrossRef] [PubMed]
67. Bermudez, Y.; Yang, H.; Cheng, J.Q.; Kruk, P.A. Pyk2/Erk 1/2 mediate Sp1- and c-Myc -dependent induction of telomerase activity by epidermal growth factor. Growth Factors 2008, 26, 1-11. [CrossRef] [PubMed]
68. Li, N.F.; Kocher, H.M.; Salako, M.A.; Obermueller, E.; Sandle, J.; Balkwill, F. A novel function of colony-stimulating factor 1 receptor in hTERT immortalization of human epithelial cells. Oncogene 2009, 28, 773-780. [CrossRef] [PubMed]
69. Bilsland, A.E.; Hoare, S.; Stevenson, K.; Plumb, J.; Gomez-Roman, N.; Cairney, C.; Burns, S.; Lafferty-Whyte, K.; Roffey, J.; Hammonds, T. et al. Dynamic telomerase gene suppression via network effects of GSK3 inhibition. PLoS ONE 2009, 4, e6459. [CrossRef] [PubMed]
70. Sitaram, R.T.; Cairney, C.J.; Grabowski, P.; Keith, W.N.; Hallberg, B.; Ljungberg, B.; Roos, G. The PTEN regulator DJ-1 is associated with hTERT expression in clear cell renal cell carcinoma. Int. J. Cancer 2009, 125, 783-790. [CrossRef] [PubMed]
71. Stefanou, N.; Papanikolaou, V.; Furukawa, Y.; Nakamura, Y.; Tsezou, A. Leptin as a critical regulator of hepatocellular carcinoma development through modulation of human telomerase reverse transcriptase. BMC Cancer 2010. [CrossRef] [PubMed]
72. Niu, C.; Yip, H.K. Neuroprotective signaling mechanisms of telomerase are regulated by brain-derived neurotrophic factor in rat spinal cord motor neurons. J. Neuropathol. Exp. Neurol. 2011, 70, 634-652. [CrossRef] [PubMed]
73. Yamashita, S.; Ogawa, K.; Ikei, T.; Udono, M.; Fujiki, T.; Katakura, Y. SIRT1 prevents replicative senescence of normal human umbilical cord fibroblast through potentiating the transcription of human telomerase reverse transcriptase gene. Biochem. Biophys. Res. Commun. 2012, 417, 630-634. [CrossRef] [PubMed]
74. Adamo, R.; Comandini, A.; Aquino, A.; Bonmassar, L.; Guglielmi, L.; Bonmassar, E.; Franzese, O. The antiretroviral agent saquinavir enhances hTERT expression and telomerase activity in human T leukaemia cells in vitro. J. Exp. Clin. Cancer Res. 2013. [CrossRef] [PubMed]
75. Wang, X.; Zhou, P.; Sun, X.; Zheng, J.; Wei, G.; Zhang, L.; Wang, H.; Yao, J.; Lu, S.; Jia, P. Acidified bile acids increase hTERT expression via c-Myc activation in human gastric cancer cells. Oncol. Rep. 2015, 33, 3038-3044. [CrossRef] [PubMed]
76. Hrdlickova, R.; Nehyba, J.; Bose, H.R., Jr. Regulation of telomerase activity by interferon regulatory factors 4 and 8 in immune cells. Mol. Cell. Biol. 2009, 29, 929-941. [CrossRef] [PubMed]
77. Koshiji, M.; Kageyama, Y.; Pete, E.A.; Horikawa, I.; Barrett, J.C.; Huang, L.E. Hif-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J. 2004, 23, 1949-1956. [CrossRef] [PubMed]
78. Cerezo, A.; Kalthoff, H.; Schuermann, M.; Schafer, B.; Boukamp, P. Dual regulation of telomerase activity through c-Myc -dependent inhibition and alternative splicing of hTERT. J. Cell Sci. 2002, 115, 1305-1312.
79. Li, H.; Xu, D.; Li, J.; Berndt, M.C.; Liu, J.P. Transforming growth factor beta suppresses human telomerase reverse transcriptase (hTERT) by Smad3 interactions with c-Myc and the hTERT gene. J. Biol. Chem. 2006, 281, 25588-25600. [CrossRef] [PubMed]
80. Yoo, Y.S.; Park, S.; Gwak, J.; Ju, B.G.; Oh, S. Involvement of transcription repressor snail in the regulation of human telomerase reverse transcriptase (hTERT) by transforming growth factor-beta. Biochem. Biophys. Res. Commun. 2015, 465, 131-136. [CrossRef] [PubMed]
81. Xiong, J.; Fan, S.; Meng, Q.; Schramm, L.; Wang, C.; Bouzahza, B.; Zhou, J.; Zafonte, B.; Goldberg, I.D.; Haddad, B.R. et al. Brca1 inhibition of telomerase activity in cultured cells. Mol. Cell. Biol. 2003, 23, 8668-8690. [CrossRef] [PubMed]
82. Zhou, C.; Liu, J. Inhibition of human telomerase reverse transcriptase gene expression by BRCA1 in human ovarian cancer cells. Biochem. Biophys. Res. Commun. 2003, 303, 130-136. [CrossRef]
83. Jang, K.J.; Kwon, G.S.; Jeong, J.W.; Kim, C.H.; Yoon, H.M.; Kim, G.Y.; Shim, J.H.; Moon, S.K.; Kim, W.J.; Choi, Y.H. Cordyceptin induces apoptosis through repressing hTERT expression and inducing extranuclear export of hTERT. J. Biosci. Bioeng. 2015, 119, 351-357. [CrossRef] [PubMed]
84. Moriai, M.; Tsuji, N.; Kobayashi, D.; Kuribayashi, K.; Watanabe, N. Down-regulation of hTERT expression plays an important role in 15-deoxy-delta12, 14-prostaglandin J2-induced apoptosis in cancer cells. Int. J. Oncol. 2009, 34, 1363-1372. [PubMed]
85. Toaldo, C.; Pizzimenti, S.; Cerbone, A.; Pettazzoni, P.; Menegatti, E.; Daniela, B.; Minelli, R.; Giglioni, B.; Dianzani, M.U.; Ferretti, C. et al. Ppargamma ligands inhibit telomerase activity and hTERT expression through modulation of the Myc /Mad/Max network in colon cancer cells. J. Cell. Mol. Med. 2010, 14, 1347-1357. [CrossRef] [PubMed]
86. Oh, S.; Song, Y.H.; Yim, J.; Kim, T.K. Identification of Mad as a repressor of the human telomerase (hTERT) gene. Oncogene 2000, 19, 1485-1490. [CrossRef] [PubMed]
87. Wahlstrom, T.; Belikov, S.; Arsenian Henriksson, M. Chromatin dynamics at the hTERT promoter during transcriptional activation and repression by c-Myc and Mnt in xenopus leavis oocytes. Exp. Cell Res. 2013, 319, 3160-3169. [CrossRef] [PubMed]
88. Yao, Y.; Bellon, M.; Shelton, S.N.; Nicot, C. Tumor suppressors p53, p63TAa, p63TAy, p73a, and p73|3 use distinct pathways to repress telomerase expression. J. Biol. Chem. 2012, 287, 20737-20747. [CrossRef] [PubMed]
89. Gabet, A.S.; Mortreux, F.; Charneau, P.; Riou, P.; Duc-Dodon, M.; Wu, Y.; Jeang, K.T.; Wattel, E. Inactivation of hTERT transcription by tax. Oncogene 2003, 22, 3734-3741. [CrossRef] [PubMed]
90. Kitagawa, Y.; Kyo, S.; Takakura, M.; Kanaya, T.; Koshida, K.; Namiki, M.; Inoue, M. Demethylating reagent 5-azacytidine inhibits telomerase activity in human prostate cancer cells through transcriptional repression of hTERT. Clin. Cancer Res. 2000, 6, 2868-2875. [PubMed]
91. Grandjenette, C.; Schnekenburger, M.; Karius, T.; Ghelfi, J.; Gaigneaux, A.; Henry, E.; Dicato, M.; Diederich, M. 5-aza-2'-deoxycytidine-mediated c-Myc down-regulation triggers telomere-dependent senescence by regulating human telomerase reverse transcriptase in chronic myeloid leukemia. Neoplasia 2014, 16, 511-528. [CrossRef] [PubMed]
92. Grand, C.L.; Han, H.; Munoz, R.M.; Weitman, S.; Von Hoff, D.D.; Hurley, L.H.; Bearss, D.J. The cationic porphyrin Tmpyp4 down-regulates c-Myc and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol. Cancer Ther. 2002, 1, 565-573. [PubMed]
93. Kanzawa, T.; Germano, I.M.; Kondo, Y.; Ito, H.; Kyo, S.; Kondo, S. Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. Br. J. Cancer 2003, 89, 922-929. [CrossRef] [PubMed]
94. Jagadeesh, S.; Kyo, S.; Banerjee, P.P. Genistein represses telomerase activity via both transcriptional and posttranslational mechanisms in human prostate cancer cells. Cancer Res. 2006, 66, 2107-2115. [CrossRef] [PubMed]
95. Liao, C.H.; Hsiao, Y.M.; Hsu, C.P.; Lin, M.Y.; Wang, J.C.; Huang, Y.L.; Ko, J.L. Transcriptionally mediated inhibition of telomerase of fungal immunomodulatory protein from ganoderma tsugae in A549 human lung adenocarcinoma cell line. Mol. Carcinog. 2006, 45, 220-229. [CrossRef] [PubMed]
96. Pizzimenti, S.; Briatore, F.; Laurora, S.; Toaldo, C.; Maggio, M.; De Grandi, M.; Meaglia, L.; Menegatti, E.; Giglioni, B.; Dianzani, M.U. et al. 4-hydroxynonenal inhibits telomerase activity and hTERT expression in human leukemic cell lines. Free Radic. Biol. Med. 2006, 40, 1578-1591. [CrossRef] [PubMed]
97. Yu, J.; Guo, Q.L.; You, Q.D.; Lin, S.S.; Li, Z.; Gu, H.Y.; Zhang, H.W.; Tan, Z.; Wang, X. Repression of telomerase reverse transcriptase mrna and hTERT promoter by gambogic acid in human gastric carcinoma cells. Cancer Chemother. Pharmacol. 2006, 58, 434-443. [CrossRef] [PubMed]
98. Moon, D.O.; Kim, M.O.; Lee, J.D.; Choi, Y.H.; Kim, G.Y. Butein suppresses c-Myc -dependent transcription and Akt-dependent phosphorylation of hTERT in human leukemia cells. Cancer Lett. 2009, 286, 172-179. [CrossRef] [PubMed]
99. Huang, S.T.; Wang, C.Y.; Yang, R.C.; Chu, C.J.; Wu, H.T.; Pang, J.H. Wogonin, an active compound in Scutellaria baicalensis, induces apoptosis and reduces telomerase activity in the HL-60 leukemia cells. Phytomedicine 2010, 17, 47-54. [CrossRef] [PubMed]
100. Zhang, Y.; Zhang, A.; Shen, C.; Zhang, B.; Rao, Z.; Wang, R.; Yang, S.; Ning, S.; Mao, G.; Fang, D. E2F1 acts as a negative feedback regulator of c-Myc induced hTERT transcription during tumorigenesis. Oncol. Rep. 2014, 32, 1273-1280. [CrossRef] [PubMed]
101. Zhang, Y.; Sun, M.; Shi, W.; Yang, Q.; Chen, C.; Wang, Z.; Zhou, X. Arsenic trioxide suppresses transcription of hTERT through down-regulation of multiple transcription factors in HL-60 leukemia cells. Toxicol. Lett. 2015, 232, 481-489. [CrossRef] [PubMed]
102. Dasgupta, P.; Sengupta, S.B. Role of diallyl disulfide-mediated cleavage of c-Myc and Sp-1 in the regulation of telomerase activity in human lymphoma cell line U937. Nutrition 2015, 31, 1031-1037. [CrossRef] [PubMed]
103. Wang, Q.; Bai, Z.; Li, X.; Hou, L.; Zhang, B. The evidences of human orphan receptor COUP-TFII inhibiting telomerase activity through decreasing hTERT transcription. Cancer Lett. 2004, 214, 81-90. [CrossRef] [PubMed]
104. Chen, W.; Qin, L.; Wang, S.; Li, M.; Shi, D.; Tian, Y.; Wang, J.; Fu, L.; Li, Z.; Guo, W. et al. CPSF4 activates telomerase reverse transcriptase and predicts poor prognosis in human lung adenocarcinomas. Mol. Oncol. 2014, 8, 704-716. [CrossRef] [PubMed]
105. Renaud, S.; Loukinov, D.; Abdullaev, Z.; Guilleret, I.; Bosman, F.T.; Lobanenkov, V.; Benhattar, J. Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene. Nucleic Acids Res. 2007, 35, 1245-1256. [CrossRef] [PubMed]
106. Min, N.Y.; Kim, J.H.; Choi, J.H.; Liang, W.; Ko, Y.J.; Rhee, S.; Bang, H.; Ham, S.W.; Park, A.J.; Lee, K.H. Selective death of cancer cells by preferential induction of reactive oxygen species in response to (—)-epigallocatechin-3-gallate. Biochem. Biophys. Res. Commun. 2012, 421, 91-97. [CrossRef] [PubMed]
107. Chen, J.; Yao, Z.X.; Chen, J.S.; Gi, Y.J.; Munoz, N.M.; Kundra, S.; Herlong, H.F.; Jeong, Y.S.; Goltsov, A.; Ohshiro, K. et al. TGF-β/β2-spectrin/CTCF-regulated tumor suppression in human stem cell disorder beckwith-wiedemann syndrome. J. Clin. Investig. 2016, 126, 527-542. [CrossRef] [PubMed]
108. Meeran, S.M.; Patel, S.N.; Tollefsbol, T.O. Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines. PLoS ONE 2010, 5, e11457. [CrossRef] [PubMed]
109. Karam, M.; Thenoz, M.; Capraro, V.; Robin, J.-P.; Pinatel, C.; Lanęon, A.; Galia, P.; Sibon, D.; Thomas, X.; Ducastelle-Lepretre, S. et al. Chromatin redistribution of the DEK oncoprotein represses hTERT transcription in leukemias. Neoplasia 2014, 16, 21-30. [CrossRef] [PubMed]
110. Crowe, D.L.; Nguyen, D.C.; Tsang, K.J.; Kyo, S. E2F-1 represses transcription of the human telomerase reverse transcriptase gene. Nucleic Acids Res. 2001, 29, 2789-2794. [CrossRef] [PubMed]
111. Lacerte, A.; Korah, J.; Roy, M.; Yang, X.J.; Lemay, S.; Lebrun, J.J. Transforming growth factor-beta inhibits telomerase through SMAD3 and E2F transcription factors. Cell Signal 2008, 20, 50-59. [CrossRef] [PubMed]
112. Gizard, F.; Nomiyama, T.; Zhao, Y.; Findeisen, H.M.; Heywood, E.B.; Jones, K.L.; Staels, B.; Bruemmer, D. The PPARalpha/p16INK4a pathway inhibits vascular smooth muscle cell proliferation by repressing cell cycle-dependent telomerase activation. Circ. Res. 2008, 103, 1155-1163. [CrossRef] [PubMed]
113. Sekaric, P.; Cherry, J.J.; Androphy, E.J. Binding of human papillomavirus type 16 E6 to E6ap is not required for activation of hTERT. J. Virol. 2008, 82, 71-76. [CrossRef] [PubMed]
114. Akutagawa, O.; Nishi, H.; Kyo, S.; Higuma, C.; Inoue, M.; Isaka, K. Early growth response-1 mediates up-regulation of telomerase in placenta. Placenta 2007, 28, 920-927. [CrossRef] [PubMed]
115. Akutagawa, O.; Nishi, H.; Kyo, S.; Terauchi, F.; Yamazawa, K.; Higuma, C.; Inoue, M.; Isaka, K. Early growth response-1 mediates downregulation of telomerase in cervical cancer. Cancer Sci. 2008, 99, 1401-1406. [CrossRef] [PubMed]
116. Grasselli, A.; Nanni, S.; Colussi, C.; Aiello, A.; Benvenuti, V.; Ragone, G.; Moretti, F.; Sacchi, A.; Bacchetti, S.; Gaetano, C. et al. Estrogen receptor-alpha and endothelial nitric oxide synthase nuclear complex regulates transcription of human telomerase. Circ. Res. 2008, 103, 34-42. [CrossRef] [PubMed]
117. Goueli, B.S.; Janknecht, R. Upregulation of the catalytic telomerase subunit by the transcription factor ER81 and oncogenic HER2/Neu, Ras, or Raf. Mol. Cell. Biol. 2003, 24, 25-35. [CrossRef]
118. Misiti, S.; Nanni, S.; Fontemaggi, G.; Cong, Y.S.; Wen, J.; Hirte, H.W.; Piaggio, G.; Sacchi, A.; Pontecorvi, A.; Bacchetti, S. et al. Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells. Mol. Cell. Biol. 2000, 20, 3764-3771. [CrossRef] [PubMed]
119. Kondoh, K.; Tsuji, N.; Asanuma, K.; Kobayashi, D.; Watanabe, N. Inhibition of estrogen receptor beta-mediated human telomerase reverse transcriptase gene transcription via the suppression of mitogen-activated protein kinase signaling plays an important role in 15-deoxy-delta(12, 14)-prostaglandin J2-induced apoptosis in cancer cells. Exp. Cell Res. 2007, 313, 3486-3496. [PubMed]
120. Kasiappan, R.; Sun, Y.; Lungchukiet, P.; Quarni, W.; Zhang, X.; Bai, W. Vitamin d suppresses leptin stimulation of cancer growth through microrna. Cancer Res. 2014, 74, 6194-6204. [CrossRef] [PubMed]
121. Marconett, C.N.; Sundar, S.N.; Tseng, M.; Tin, A.S.; Tran, K.Q.; Mahuron, K.M.; Bjeldanes, L.F.; Firestone, G.L. Indole-3-carbinol downregulation of telomerase gene expression requires the inhibition of estrogen receptor-alpha and Sp1 transcription factor interactions within the hTERT promoter and mediates the g1 cell cycle arrest of human breast cancer cells. Carcinogenesis 2011, 32, 1315-1323. [CrossRef] [PubMed]
122. Wang, Z.; Kyo, S.; Takakura, M.; Tanaka, M.; Yatabe, N.; Maida, Y.; Fujiwara, M.; Hayakawa, J.; Ohmichi, M.; Koike, K. et al. Progesterone regulates human telomerase reverse transcriptase gene expression via activation of mitogen-activated protein kinase signaling pathway. Cancer Res. 2000, 60, 5376-5381. [PubMed]
123. Hsu, C.P.; Lee, L.W.; Tang, S.C.; Hsin, I.L.; Lin, Y.W.; Ko, J.L. Epidermal growth factor activates telomerase activity by direct binding of ETS-2 to hTERT promoter in lung cancer cells. Tumour Biol. 2015, 36, 5389-5398. [CrossRef] [PubMed]
124. Maida, Y.; Kyo, S.; Kanaya, T.; Wang, Z.; Yatabe, N.; Tanaka, M.; Nakamura, M.; Ohmichi, M.; Gotoh, N.; Murakami, S. et al. Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via map kinase signaling pathway. Oncogene 2002, 21, 4071-079. [CrossRef] [PubMed]
125. Xiao, X.; Athanasiou, M.; Sidorov, I.A.; Horikawa, I.; Cremona, G.; Blair, D.; Barret, J.C.; Dimitrov, D.S. Role of Ets/Id proteins for telomerase regulation in human cancer cells. Exp. Mol. Pathol. 2003, 75, 238-247. [CrossRef]
126. Takahashi, A.; Higashino, F.; Aoyagi, M.; Yoshida, K.; Itoh, M.; Kyo, S.; Ohno, T.; Taira, T.; Ariga, H.; Nakajima, K. et al. EWS/EST fusions activate telomerase in ewing's tumors. Cancer Res. 2003, 63, 8338-8344. [PubMed]
127. Ogawa, D.; Nomiyama, T.; Nakamachi, T.; Heywood, E.B.; Stone, J.F.; Berger, J.P.; Law, R.E.; Bruemmer, D. Activation of peroxisome proliferator-activated receptor gamma suppresses telomerase activity in vascular smooth muscle cells. Circ. Res. 2006, 98, e50-e59. [CrossRef] [PubMed]
128. Mazumdar, T.; Sandhu, R.; Qadan, M.; DeVecchio, J.; Magloire, V.; Agyeman, A.; Li, B.; Houghton, J.A. Hedgehog signaling regulates telomerase reverse transcriptase in human cancer cells. PLoS ONE 2013, 8, e75253. [CrossRef] [PubMed]
129. Chen, W.; Dong, Q.; Shin, K.H.; Kim, R.H.; Oh, J.E.; Park, N.H.; Kang, M.K. Grainyhead-like 2 enhances the human telomerase reverse transcriptase gene expression by inhibiting DNA methylation at the 5'-CPG island in normal human keratinocytes. J. Biol. Chem. 2010, 285, 40852-40863. [CrossRef]
130. Kang, X.; Chen, W.; Kim, R.H.; Kang, M.K.; Park, N.H. Regulation of the hTERT promoter activity by MSH2, the hnRNPs K and D, and GRHL2 in human oral squamous cell carcinoma cells. Oncogene 2009, 28, 565-574. [CrossRef] [PubMed]
131. Yatabe, N.; Kyo, S.; Maida, Y.; Nishi, H.; Nakamura, M.; Kanaya, T.; Tanaka, M.; Isaka, K.; Ogawa, S.; Inoue, M. HIF-1-mediated activation of telomerase in cervical cancer cells. Oncogene 2004, 23, 3708-3715. [CrossRef] [PubMed]
132. Nishi, H.; Nakada, T.; Kyo, S.; Inoue, M.; Shay, J.W.; Isaka, K. Hypoxia-inducible factor 1 mediates upregulation of telomerase (hTERT). Mol. Cell. Biol. 2004, 24, 6076-6083. [CrossRef] [PubMed]
133. Yang, K.; Zheng, D.; Deng, X.; Bai, L.; Xu, Y.; Cong, Y.S. Lysophosphatidic acid activates telomerase in ovarian cancer cells through hypoxia-inducible factor-1a and the PI3K pathway. J. Cell. Biochem. 2008, 105, 1194-1201. [CrossRef] [PubMed]
134. Lou, F.; Chen, X.; Jalink, M.; Zhu, Q.; Ge, N.; Zhao, S.; Fang, X.; Fan, Y.; Bjorkholm, M.; Liu, Z. et al. The opposing effect of hypoxia-inducible factor-2a on expression of telomerase reverse transcriptase. Mol. Cancer Res. 2007, 5, 793-800. [CrossRef] [PubMed]
135. Kim, R.H.; Kim, R.; Chen, W.; Hu, S.; Shin, K.H.; Park, N.H.; Kang, M.K. Association of HSP90 to the hTERT promoter is necessary for hTERT expression in human oral cancer cells. Carcinogenesis 2008, 29, 2425-2431. [CrossRef] [PubMed]
136. Hara, T.; Mizuguchi, M.; Fujii, M.; Nakamura, M. Kruppel-like factor 2 represses transcription of the telomerase catalytic subunit human telomerase reverse transcriptase (hTERT) in human t cells. J. Biol. Chem. 2015, 290, 8758-8763. [CrossRef] [PubMed]
137. Wong, C.W.; Hou, P.S.; Tseng, S.F.; Chien, C.L.; Wu, K.J.; Chen, H.F.; Ho, H.N.; Kyo, S.; Teng, S.C. Kruppel-like transcription factor 4 contributes to maintenance of telomerase activity in stem cells. Stem Cells 2010, 28, 1510-1517. [CrossRef] [PubMed]
138. Zhu, Q.; Liu, C.; Ge, Z.; Fang, X.; Zhang, X.; Straat, K.; Bjorkholm, M.; Xu, D. Lysine-specific demethylase 1 (LSD1) is required for the transcriptional repression of the telomerase reverse transcriptase (hTERT) gene. PLoS ONE 2008, 3, e1446. [CrossRef] [PubMed]
139. Gunes, C.; Lichtsteiner, S.; Vasserot, A.P.; Englert, C. Expression of the hTERT gene is regulated at the level of transcriptional initiation and repressed by mad1. Cancer Res. 2000, 60, 2116-2121. [PubMed]
140. Farhana, L.; Dawson, M.I.; Fontana, J.A. Down regulation of miR-202 modulates Mxd1 and Sin3A repressor complexes to induce apoptosis of pancreatic cancer cells. Cancer Biol. Ther. 2015, 16, 115-124. [CrossRef] [PubMed]
141. Xu, M.; Katzenellenbogen, R.A.; Grandori, C.; Galloway, D.A. An unbiased in vivo screen reveals multiple transcription factors that control HPV E6-regulated hTERT in keratinocytes. Virology 2013, 446, 17-24. [CrossRef] [PubMed]
142. Su, J.M.; Lai, X.M.; Lan, K.H.; Li, C.P.; Chao, Y.; Yen, S.H.; Chang, F.Y.; Lee, S.D.; Lee, W.P. X protein of hepatitis B virus functions as a transcriptional corepressor on the human telomerase promoter. Hepatology 2007, 46, 402-413. [CrossRef] [PubMed]
143. Shi, L.; Li, M.; Su, B. MCPH1/BRIT1 represses transcription of the human telomerase reverse transcriptase gene. Gene 2012, 495, 1-9. [CrossRef] [PubMed]
144. Hashimoto, M.; Kyo, S.; Hua, X.; Tahara, H.; Nakajima, M.; Takakura, M.; Sakaguchi, J.; Maida, Y.; Nakamura, M.; Ikoma, T. et al. Role of menin in the regulation of telomerase activity in normal and cancer cells. Int. J. Oncol. 2008, 33, 333-340. [PubMed]
145. Borowiak, M.; Kuhlmann, A.S.; Girard, S.; Gazzolo, L.; Mesnard, J.M.; Jalinot, P.; Dodon, M.D. HTLV-1 BZIP factor impedes the menin tumor suppressor and upregulates jund-mediated transcription of the hTERT gene. Carcinogenesis 2013, 34, 2664-2672. [CrossRef] [PubMed]
146. Fujimoto, K.; Kyo, S.; Takakura, M.; Kanaya, T.; Kitagawa, Y.; Itoh, H.; Takahashi, M.; Inoue, M. Identification and characterization of negative regulatory elements of the human telomerase catalytic subunit (hTERT) gene promoter: Possible role of MZF-2 in transcriptional repression of hTERT. Nucleic Acids Res. 2000, 28, 2557-2562. [CrossRef] [PubMed]
147. Gizard, F.; Heywood, E.B.; Findeisen, H.M.; Zhao, Y.; Jones, K.L.; Cudejko, C.; Post, G.R.; Staels, B.; Bruemmer, D. Telomerase activation in atherosclerosis and induction of telomerase reverse transcriptase expression by inflammatory stimuli in macrophages. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 245-252. [CrossRef] [PubMed]
148. Aravindan, N.; Veeraraghavan, J.; Madhusoodhanan, R.; Herman, T.S.; Natarajan, M. Curcumin regulates low-linear energy transfer gamma-radiation-induced NFKB-dependent telomerase activity in human neuroblastoma cells. Int. J. Radiat. Oncol. Biol. Phys. 2011, 79, 1206-1215. [CrossRef] [PubMed]
149. Chung, S.S.; Aroh, C.; Vadgama, J.V. Constitutive activation of STAT3 signaling regulates hTERT and promotes stem cell-like traits in human breast cancer cells. PLoS ONE 2013, 8, e83971. [CrossRef] [PubMed]
150. Bellon, M.; Nicot, C. Central role of PI3K in transcriptional activation of hTERT in HTLV-I-Infected cells. Blood 2008, 112, 2946-2955. [CrossRef] [PubMed]
151. Kawagoe, J.; Ohmichi, M.; Takahashi, T.; Ohshima, C.; Mabuchi, S.; Takahashi, K.; Igarashi, H.; Mori-Abe, A.; Saitoh, M.; Du, B. et al. Raloxifene inhibits estrogen-induced up-regulation of telomerase activity in a human breast cancer cell line. J. Biol. Chem. 2003, 278, 43363-43372. [CrossRef] [PubMed]
152. Natarajan, M.; Mohan, S.; Konopinski, R.; Otto, R.A.; Herman, T.S. Induced telomerase activity in primary aortic endothelial cells by low-let gamma-radiation is mediated through NF-Kb activation. Br. J. Radiol. 2008, 81, 711-720. [CrossRef] [PubMed]
153. Aravindan, N.; Aravindan, S.; Herman, T.S.; Natarajan, M. EGFR tyrosine kinase inhibitor pelitinib regulates radiation-induced p65-dependent telomerase activation in squamous cell carcinoma. Radiat. Res. 2013, 179, 304-312. [CrossRef] [PubMed]
154. Chebel, A.; Rouault, J.P.; Urbanowicz, I.; Baseggio, L.; Chien, W.W.; Salles, G.; Ffrench, M. Transcriptional activation of hTERT, the human telomerase reverse transcriptase, by nuclear factor of activated T cells. J. Biol. Chem. 2009, 284, 35725-35734. [CrossRef] [PubMed]
155. Galloway, D.A.; Gewin, L.C.; Myers, H.; Luo, W.; Grandori, C.; Katzenellenbogen, R.A.; McDougall, J.K. Regulation of telomerase by human papillomaviruses. Cold Spring Harb. Symp. Quant. Biol. 2005, 70, 209-215. [CrossRef] [PubMed]
156. Bougel, S.; Renaud, S.; Braunschweig, R.; Loukinov, D.; Morse, H.C., III; Bosman, F.T.; Lobanenkov, V.; Benhattar, J. PAX5 activates the transcription of the human telomerase reverse transcriptase gene in B cells. J. Pathol. 2010, 220, 87-96. [CrossRef] [PubMed]
157. Chen, Y.J.; Campbell, H.G.; Wiles, A.K.; Eccles, M.R.; Reddel, R.R.; Braithwaite, A.W.; Royds, J.A. PAX8 regulates telomerase reverse transcriptase and telomerase RNA component in glioma. Cancer Res. 2008, 68, 5724-5732. [CrossRef] [PubMed]
158. Qi, D.L.; Ohhira, T.; Fujisaki, C.; Inoue, T.; Ohta, T.; Osaki, M.; Ohshiro, E.; Seko, T.; Aoki, S.; Oshimura, M. et al. Identification of PITX1 as a TERT suppressor gene located on human chromosome 5. Mol. Cell. Biol. 2011, 31, 1624-1636. [CrossRef] [PubMed]
159. Ohira, T.; Naohiro, S.; Nakayama, Y.; Osaki, M.; Okada, F.; Oshimura, M.; Kugoh, H. miR-19b regulates hTERT mRNA expression through targeting PITX1 mRNA in melanoma cells. Sci. Rep. 2015. [CrossRef] [PubMed]
160. Luan, F.; Liu, H.; Gao, L.; Liu, J.; Sun, Z.; Ju, Y.; Hou, N.; Guo, C.; Liang, X.; Zhang, L. et al. Hepatitis B virus protein preS2 potentially promotes HCC development via its transcriptional activation of hTERT. Gut 2009, 58, 1528-1537. [CrossRef] [PubMed]
161. Li, W.; Zeng, J.; Li, Q.; Zhao, L.; Liu, T.; Bjorkholm, M.; Jia, J.; Xu, D. Reptin is required for the transcription of telomerase reverse transcriptase and over-expressed in gastric cancer. Mol. Cancer 2010. [CrossRef] [PubMed]
162. Chen, W.; Lu, J.; Qin, Y.; Wang, J.; Tian, Y.; Shi, D.; Wang, S.; Xiao, Y.; Dai, M.; Liu, L. et al. Ret finger protein-like 3 promotes tumor cell growth by activating telomerase reverse transcriptase expression in human lung cancer cells. Oncotarget 2014, 5, 11909-11923. [CrossRef] [PubMed]
163. Qin, Y.; Chen, W.; Xiao, Y.; Yu, W.; Cai, X.; Dai, M.; Xu, T.; Huang, W.; Guo, W.; Deng, W. et al. RFPL3 and CBP synergistically upregulate hTERT activity and promote lung cancer growth. Oncotarget 2015, 6, 27130-27145. [CrossRef] [PubMed]
164. Guo, W.; Lu, J.; Dai, M.; Wu, T.; Yu, Z.; Wang, J.; Chen, W.; Shi, D.; Yu, W.; Xiao, Y. et al. Transcriptional coactivator cbp upregulates hTERT expression and tumor growth and predicts poor prognosis in human lung cancers. Oncotarget 2014, 5, 9349-9361. [CrossRef] [PubMed]
165. Knight, J.S.; Cotter, M.A., II; Robertson, E.S. The latency-associated nuclear antigen of kaposi's sarcoma-associated herpesvirus transactivates the telomerase reverse transcriptase promoter. J. Biol. Chem. 2001, 276, 22971-22978. [CrossRef] [PubMed]
166. Verma, S.C.; Borah, S.; Robertson, E.S. Latency-associated nuclear antigen of kaposi's sarcoma-associated herpesvirus up-regulates transcription of human telomerase reverse transcriptase promoter through interaction with transcription factor Sp1. J. Virol. 2004, 78, 10348-10359. [CrossRef] [PubMed]
167. Chau, M.N.; El Touny, L.H.; Jagadeesh, S.; Banerjee, P.P. Physiologically achievable concentrations of genistein enhance telomerase activity in prostate cancer cells via the activation of STAT3. Carcinogenesis 2007, 28, 2282-2290. [CrossRef] [PubMed]
168. Liu, L.; Ishihara, K.; Ichimura, T.; Fujita, N.; Hino, S.; Tomita, S.; Watanabe, S.; Saitoh, N.; Ito, T.; Nakao, M. MCAF1/AM is involved in Sp1-mediated maintenance of cancer-associated telomerase activity. J. Biol. Chem. 2009, 284, 5165-5174. [CrossRef] [PubMed]
169. Liu, H.; Shi, W.; Luan, F.; Xu, S.; Yang, F.; Sun, W.; Liu, J.; Ma, C. Hepatitis B virus X protein upregulates transcriptional activation of human telomerase reverse transcriptase. Virus Genes 2010, 40, 174-182. [CrossRef] [PubMed]
170. Li, A.Y.; Lin, H.H.; Kuo, C.Y.; Shih, H.M.; Wang, C.C.; Yen, Y.; Ann, D.K. High-mobility group a2 protein modulates hTERT transcription to promote tumorigenesis. Mol. Cell. Biol. 2011, 31, 2605-2617. [CrossRef] [PubMed]
171. Xu, D.; Wang, Q.; Gruber, A.; Bjorkholm, M.; Chen, Z.; Zaid, A.; Selivanova, G.; Peterson, C.; Wiman, K.G.; Pisa, P. Downregulation of telomerase reverse transcriptase mrna expression by wild type p53 in human tumor cells. Oncogene 2000, 19, 5123-5133. [CrossRef] [PubMed]
172. Beitzinger, M.; Oswald, C.; Beinoraviciute-Kellner, R.; Stiewe, T. Regulation of telomerase activity by the p53 family member p73. Oncogene 2006, 25, 813-826. [CrossRef] [PubMed]
173. Racek, T.; Mise, N.; Li, Z.; Stoll, A.; Putzer, B.M. C-terminal p73 isoforms repress transcriptional activity of the human telomerase reverse transcriptase (hTERT) promoter. J. Biol. Chem. 2005, 280, 40402-40405. [CrossRef] [PubMed]
174. Wooten, L.G.; Ogretmen, B. Sp1/Sp3-dependent regulation of human telomerase reverse transcriptase promoter activity by the bioactive sphingolipid ceramide. J. Biol. Chem. 2005, 280, 28867-28876. [CrossRef] [PubMed]
175. Lee, D.; Kim, H.Z.; Jeong, K.W.; Shim, Y.S.; Horikawa, I.; Barrett, J.C.; Choe, J. Human papillomavirus E2 down-regulates the human telomerase reverse transcriptase promoter. J. Biol. Chem. 2002, 277, 27748-27756. [CrossRef] [PubMed]
176. Won, J.; Yim, J.; Kim, T.K. Opposing regulatory roles of E2F in human telomerase reverse transcriptase (hTERT) gene expression in human tumor and normal somatic cells. FASEB J. 2002, 16, 1943-1945. [CrossRef] [PubMed]
177. Saito, M.; Nakagawa, K.; Hamada, K.; Hirose, S.; Harada, H.; Kohno, S.; Nagato, S.; Ohnishi, T. Introduction of p16INK4a inhibits telomerase activity through transcriptional suppression of human telomerase reverse transcriptase expression in human gliomas. Int. J. Oncol. 2004, 24, 1213-1220. [CrossRef] [PubMed]
178. Lin, P.C.; Lin, S.Z.; Chen, Y.L.; Chang, J.S.; Ho, L.I.; Liu, P.Y.; Chang, L.F.; Harn, Y.C.; Chen, S.P.; Sun, L.Y. et al. Butylidenephthalide suppresses human telomerase reverse transcriptase (TERT) in human glioblastomas. Ann. Surg. Oncol. 2011, 18, 3514-3527. [CrossRef] [PubMed]
179. Shapira, S.; Granot, G.; Mor-Tzuntz, R.; Raanani, P.; Uziel, O.; Lahav, M.; Shpilberg, O. Second-generation tyrosine kinase inhibitors reduce telomerase activity in K562 cells. Cancer Lett. 2012, 323, 223-231. [CrossRef] [PubMed]
180. Deeb, D.; Brigolin, C.; Gao, X.; Liu, Y.; Pindolia, K.R.; Gautam, S.C. Induction of apoptosis in pancreatic cancer cells by CDDO-Me involves repression of telomerase through epigenetic pathways. J. Carcinog. Mutagen. 2014. [CrossRef] [PubMed]
181. Zhang, D.; Sun, X.; Liu, J.; Xie, X.; Cui, W.; Zhu, Y. Homocysteine accelerates senescence of endothelial cells via DNA hypomethylation of human telomerase reverse transcriptase. Arterioscler. Thromb. Vasc. Biol. 2015, 35, 71-78. [CrossRef] [PubMed]
182. Long, C.; Wang, J.; Guo, W.; Wang, H.; Wang, C.; Liu, Y.; Sun, X. Triptolide inhibits transcription of hTERT through down-regulation of transcription factor specificity protein 1 in primary effusion lymphoma cells. Biochem. Biophys. Res. Commun. 2016, 469, 87-93. [CrossRef] [PubMed]
183. Won, J.; Yim, J.; Kim, T.K. Sp1 and Sp3 recruit histone deacetylase to repress transcription of human telomerase reverse transcriptase (hTERT) promoter in normal human somatic cells. J. Biol. Chem. 2002, 277, 38230-38238. [CrossRef] [PubMed]
184. Glasspool, R.M.; Burns, S.; Hoare, S.F.; Svensson, C.; Keith, W.N. The hTERT and hTERC telomerase gene promoters are activated by the second exon of the adenoviral protein, E1 A, identifying the transcriptional corepressor CtBP as a potential rearessor of both genes. Neoplasia 2005, 7, 614-622. [CrossRef] [PubMed]
185. Fujiki, T.; Miura, T.; Maura, M.; Shiraishi, H.; Nishimura, S.; Imada, Y.; Uehara, N.; Tashiro, K.; Shirahata, S.; Katakura, Y. TAK1 represses transcription of the human telomerase reverse transcriptase gene. Oncogene 2007, 26, 5258-5266. [CrossRef] [PubMed]
186. Wooten-Blanks, L.G.; Song, P.; Senkal, C.E.; Ogretmen, B. Mechanisms of ceramide-mediated repression of the human telomerase reverse transcriptase promoter via deacetylation of Sp3 by histone deacetylase 1. FASEB J. 2007, 21, 3386-3397. [CrossRef] [PubMed]
187. Chen, R.; Zhu, J.; Dong, Y.; He, C.; Hu, X. Suppressor of Ty homolog-5, a novel tumor-specific human telomerase reverse transcriptase promoter-binding protein and activator in colon cancer cells. Oncotarget 2015, 6, 32841-32855. [PubMed]
188. Ren, H.; Zhao, T.; Wang, X.; Gao, C.; Wang, J.; Yu, M.; Hao, J. Leptin upregulates telomerase activity and transcription of human telomerase reverse transcriptase in MCF-7 breast cancer cells. Biochem. Biophys. Res. Commun. 2010, 394, 59-63. [CrossRef] [PubMed]
189. Nakatake, M.; Kakiuchi, Y.; Sasaki, N.; Murakami-Murofushi, K.; Yamada, O. STAT3 and PKC differentially regulate telomerase activity during megakaryocytic differentiation of K562 cells. Cell Cycle 2007, 6, 1496-1501. [CrossRef] [PubMed]
190. Konnikova, L.; Simeone, M.C.; Kruger, M.M.; Kotecki, M.; Cochran, B.H. Signal transducer and activator of transcription 3 (STAT3) regulates human telomerase reverse transcriptase (hTERT) expression in human cancer and primary cells. Cancer Res. 2005, 65, 6516-6520. [CrossRef] [PubMed]
191. Wang, Y.Y.; Sun, G.; Luo, H.; Wang, X.F.; Lan, F.M.; Yue, X.; Fu, L.S.; Pu, P.Y.; Kang, C.S.; Liu, N. et al. MiR-21 modulates hTERT through a STAT3-dependent manner on glioblastoma cell growth. CNS Neurosci. Ther. 2012, 18, 722-728. [CrossRef] [PubMed]
192. Guo, N.; Cheng, D.; Li, Z.H.; Zhou, Q.B.; Zhou, J.J.; Lin, Q.; Zeng, B.; Liao, Q.; Chen, R.F. Transfection of HCVc improves hTERT expression through STAT3 pathway by epigenetic regulation in Huh7 cells. J. Cell. Biochem. 2012, 113, 3419-3426. [CrossRef] [PubMed]
193. Yamada, O.; Ozaki, K.; Akiyama, M.; Kawauchi, K. JAK-STAT and JAK-PI3K-mTORC1 pathways regulate telomerase transcriptionally and posttranslationally in atl cells. Mol. Cancer Ther. 2012, 11, 1112-1121. [CrossRef] [PubMed]
194. Yamada, O.; Ozaki, K.; Furukawa, T.; Machida, M.; Wang, Y.H.; Motoji, T.; Mitsuishi, T.; Akiyama, M.; Yamada, H.; Kawauchi, K. et al. Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and mdr1. Cell Signal 2011, 23, 1119-1127. [CrossRef] [PubMed]
195. Akiyama, M.; Kawano, T.; Mikami-Terao, Y.; Agawa-Ohta, M.; Yamada, O.; Ida, H.; Yamada, H. Erythropoietin activates telomerase through transcriptional and posttranscriptional regulation in human erythroleukemic JAS-REN-A cells. Leuk. Res. 2011, 35, 416-418. [CrossRef] [PubMed]
196. Prade-Houdellier, N.; Frebet, E.; Demur, C.; Gautier, E.F.; Delhommeau, F.; Bennaceur-Griscelli, A.L.; Gaudin, C.; Martinel, V.; Laurent, G.; Mansat-De Mas, V. et al. Human telomerase is regulated by erythropoietin and transforming growth factor-β in human erythroid progenitor cells. Leukemia 2007, 21, 2304-2310. [CrossRef] [PubMed]
197. Terme, J.M.; Mocquet, V.; Kuhlmann, A.S.; Zane, L.; Mortreux, F.; Wattel, E.; Duc Dodon, M.; Jalinot, P. Inhibition of the hTERT promoter by the proto-oncogenic protein TAL1. Leukemia 2009, 23, 2081-2089. [CrossRef] [PubMed]
198. Tang, Z.; Zhao, Y.; Mei, F.; Yang, S.; Li, X.; Lv, J.; Hou, L.; Zhang, B. Molecular cloning and characterization of a human gene involved in transcriptional regulation of hTERT. Biochem. Biophys. Res. Commun. 2004, 324, 1324-1332. [CrossRef] [PubMed]
199. Hsu, C.C.; Chen, C.H.; Hsu, T.I.; Hung, J.J.; Ko, J.L.; Zhang, B.; Lee, Y.C.; Chen, H.K.; Chang, W.C.; Lin, D.Y. The 58-kDa microspherule protein (MSP58) represses human telomerase reverse transcriptase (hTERT) gene expression and cell proliferation by interacting with telomerase transcriptional element-interacting factor (TEIF). Biochim. Biophys. Acta 2014, 1843, 565-579. [CrossRef] [PubMed]
200. Goueli, B.S.; Janknecht, R. Regulation of telomerase reverse transcriptase gene activity by upstream stimulatory factor. Oncogene 2003, 22, 8042-8047. [CrossRef] [PubMed]
201. Yago, M.; Ohki, R.; Hatakeyama, S.; Fujita, T.; Ishikawa, F. Variant forms of upstream stimulatory factors (USFs) control the promoter activity of hTERT, the human gene encoding the catalytic subunit of telomerase. FEBS Lett. 2002, 520, 40-46. [CrossRef]
202. Chang, J.T.; Yang, H.T.; Wang, T.C.; Cheng, A.J. Upstream stimulatory factor (USF) as a transcriptional suppressor of human telomerase reverse transcriptase (hTERT) in oral cancer cells. Mol. Carcinog. 2005, 44, 183-192. [CrossRef] [PubMed]
203. Ikeda, N.; Uemura, H.; Ishiguro, H.; Hori, M.; Hosaka, M.; Kyo, S.; Miyamoto, K.; Takeda, E.; Kubota, Y. Combination treatment with 1 a, 25-dihydroxyvitamin D3 and 9-Cis-Retinoic acid directly inhibits human telomerase reverse transcriptase transcription in prostate cancer cells. Mol. Cancer Ther. 2003, 2, 739-746. [PubMed]
204. Oh, S.; Song, Y.; Yim, J.; Kim, T.K. The wilms' tumor 1 tumor suppressor gene represses transcription of the human telomerase reverse transcriptase gene. J. Biol. Chem. 1999, 274, 37473-37478. [CrossRef] [PubMed]
205. Veldman, T.; Horikawa, I.; Barrett, J.C.; Schlegel, R. Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein. J. Virol. 2001, 75, 4467-4472. [CrossRef] [PubMed]
206. Kanzawa, T.; Komata, T.; Kyo, S.; Germano, I.M.; Kondo, Y.; Kondo, S. Down-regulation of telomerase activity in malignant glioma cells by p27KIP1. Int. J. Oncol. 2003, 23, 1703-1708. [CrossRef] [PubMed]
207. Yoon, J.H.; Seo, H.S.; Choi, W.S.; Kim, O.; Nam, S.W.; Lee, J.Y.; Park, W.S. Gastrokine 1 induces senescence and apoptosis through regulating telomere length in gastric cancer. Oncotarget 2014, 5, 11695-11708. [CrossRef] [PubMed]
208. Kirkpatrick, K.L.; Newbold, R.F.; Mokbel, K. There is no correlation between c-Myc mRNA expression and telomerase activity in human breast cancer. Int. Semin. Surg. Oncol. 2004. [CrossRef] [PubMed]
209. Elkak, A.E.; Meligonis, G.; Salhab, M.; Mitchell, B.; Blake, J.R.; Newbold, R.F.; Mokbel, K. hTERT protein expression is independent of clinicopathological parameters and c-Myc protein expression in human breast cancer. J. Carcinog. 2005. [CrossRef]
210. Nakagawa, M.; Koyanagi, M.; Tanabe, K.; Takahashi, K.; Ichisaka, T.; Aoi, T.; Okita, K.; Mochiduki, Y.; Takizawa, N.; Yamanaka, S. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat. Biotechnol. 2008, 26, 101-106. [CrossRef] [PubMed]
211. Ghosh, A.; Saginc, G.; Leow, S.C.; Khattar, E.; Shin, E.M.; Yan, T.D.; Wong, M.; Zhang, Z.; Li, G.; Sung, W.K. et al. Telomerase directly regulates NF-KB-dependent transcription. Nat. Cell Biol. 2012, 14, 1270-1281. [CrossRef] [PubMed]
212. Ding, D.; Xi, P.; Zhou, J.; Wang, M.; Cong, Y.S. Human telomerase reverse transcriptase regulates mmp expression independently of telomerase activity via NF-KB-dependent transcription. FASEB J. 2013, 27, 4375-4383. [CrossRef] [PubMed]
213. Li, Y.; Zhou, Q.L.; Sun, W.; Chandrasekharan, P.; Cheng, H.S.; Ying, Z.; Lakshmanan, M.; Raju, A.; Tenen, D.G.; Cheng, S.Y. et al. Non-canonical NF-KB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation. Nat. Cell Biol. 2015, 17, 1327-1338. [CrossRef] [PubMed]
214. Wang, X.H.; Liu, B.R.; Qu, B.; Xing, H.; Gao, S.L.; Yin, J.M.; Wang, X.F.; Cheng, Y.Q. Silencing STAT3 may inhibit cell growth through regulating signaling pathway, telomerase, cell cycle, apoptosis and angiogenesis in hepatocellular carcinoma: Potential uses for gene therapy. Neoplasma 2011, 58, 158-171. [CrossRef] [PubMed]
215. Boggess, J.F.; Zhou, C.; Bae-Jump, V.L.; Gehrig, P.A.; Whang, Y.E. Estrogen-receptor-dependent regulation of telomerase activity in human endometrial cancer cell lines. Gynecol. Oncol. 2006, 103, 417-424. [CrossRef] [PubMed]
216. Briatore, F.; Barrera, G.; Pizzimenti, S.; Toaldo, C.; Casa, C.D.; Laurora, S.; Pettazzoni, P.; Dianzani, M.U.; Ferrero, D. Increase of telomerase activity and hTERT expression in myelodysplastic syndromes. Cancer Biol. Ther. 2009, 8, 883-889. [CrossRef] [PubMed]
217. Meeran, S.M.; Patel, S.N.; Chan, T.H.; Tollefsbol, T.O. A novel prodrug of epigallocatechin-3-gallate: Differential epigenetic hTERT repression in human breast cancer cells. Cancer Prev. Res. 2011, 4, 1243-1254. [CrossRef] [PubMed]
218. Chen, H.J.; Yu, R.A.; He, L.F.; An, S.J.; Wu, Z.G.; Yang, K.D.; Chen, X.M. Inhibitory effects of selenium on telomerase activity and hTERT expression in cadmium-transformed 16HBE cells. Biomed. Environ. Sci. 2007, 20, 307-312. [PubMed]
219. Cheng, D.; Zhao, Y.; Wang, S.; Jia, W.; Kang, J.; Zhu, J. Human telomerase reverse transcriptase (hTERT) transcription requires Sp1/Sp3 binding to the promoter and a permissive chromatin environment. J. Biol. Chem. 2015, 290, 30193-30203. [CrossRef] [PubMed]
220. Pang, J.X.; Chen, X.Y.; Wu, S.G. Regulation of telomerase activity in Jurkat T cells by transcription factors Sp1 and Sp3. Di Yi Jun Yi Da Xue Xue Bao 2002, 22, 481-485. [PubMed]
221. Eldholm, V.; Haugen, A.; Zienolddiny, S. Ctcf mediates the TERT enhancer-promoter interactions in lung cancer cells: Identification of a novel enhancer region involved in the regulation of TERT gene. Int. J. Cancer 2014, 134, 2305-2313. [CrossRef] [PubMed]
222. Jiang, F.; Bao, J.; Li, P.; Nicosia, S.V.; Bai, W. Induction of ovarian cancer cell apoptosis by 1, 25-dihydroxyvitamin D3 through the down-regulation of telomerase. J. Biol. Chem. 2004, 279, 53213-53221. [CrossRef] [PubMed]
223. Kasiappan, R.; Shen, Z.; Tse, A.K.; Jinwal, U.; Tang, J.; Lungchukiet, P.; Sun, Y.; Kruk, P.; Nicosia, S.V.; Zhang, X. et al. 1, 25-Dihydroxyvitamin d3 suppresses telomerase expression and human cancer growth through microrna-498. J. Biol. Chem. 2012, 287, 41297-41309. [CrossRef] [PubMed]
224. Kanaya, T.; Kyo, S.; Hamada, K.; Takakura, M.; Kitagawa, Y.; Harada, H.; Inoue, M. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Clin. Cancer Res. 2000, 6, 1239-1247. [PubMed]
225. Saito, T.; Akaike, K.; Kurisaki-Arakawa, A.; Toda-Ishii, M.; Mukaihara, K.; Suehara, Y.; Takagi, T.; Kaneko, K.; Yao, T. Promoter mutations are rare in bone and soft tissue sarcomas of japanese patients. Mol. Clin. Oncol. 2016, 4, 61-64. [CrossRef] [PubMed]
226. Hou, M.; Wang, X.; Popov, N.; Zhang, A.; Zhao, X.; Zhou, R.; Zetterberg, A.; Bjorkholm, M.; Henriksson, M.; Gruber, A. et al. The histone deacetylase inhibitor trichostatin a derepresses the telomerase reverse transcriptase (hTERT) gene in human cells. Exp. Cell Res. 2002, 274, 25-34. [CrossRef] [PubMed]
227. Takakura, M.; Kyo, S.; Sowa, Y.; Wang, Z.; Yatabe, N.; Maida, Y.; Tanaka, M.; Inoue, M. Telomerase activation by histone deacetylase inhibitor in normal cells. Nucleic Acids Res. 2001, 29, 3006-3011. [CrossRef] [PubMed]
228. Varshney, A.; Ramakrishnan, S.K.; Sharma, A.; Santosh, B.; Bala, J.; Yadava, P.K.; Jaiswal, R.K. Global expression profile of telomerase-associated genes in HeLa cells. Gene 2014, 547, 211-217. [CrossRef] [PubMed]
229. Atkinson, S.P.; Hoare, S.F.; Glasspool, R.M.; Keith, W.N. Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters. Cancer Res. 2005, 65, 7585-7590. [PubMed]
230. Wang, Y.; Chen, T.; Yan, H.; Qi, H.; Deng, C.; Ye, T.; Zhou, S.; Li, F.R. Role of histone deacetylase inhibitors in the aging of human umbilical cord mesenchymal stem cells. J. Cell. Biochem. 2013, 114, 2231-2239. [CrossRef] [PubMed]
231. Haigis, M.C.; Guarente, L.P. Mammalian sirtuins—Emerging roles in physiology, aging, and calorie restriction. Genes Dev. 2006, 20, 2913-2921. [CrossRef] [PubMed]
232. Chen, H.C.; Jeng, Y.M.; Yuan, R.H.; Hsu, H.C.; Chen, Y.L. SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis. Ann. Surg. Oncol. 2012, 19, 2011-2019. [CrossRef] [PubMed]
233. Mao, B.; Zhao, G.; Lv, X.; Chen, H.Z.; Xue, Z.; Yang, B.; Liu, D.P.; Liang, C.C. SIRT1 deacetylates c-Myc and promotes c-Myc /max association. Int. J. Biochem. Cell Biol. 2011, 43, 1573-1581. [CrossRef] [PubMed]
234. Chen, J.; Zhang, B.; Wong, N.; Lo, A.W.; To, K.F.; Chan, A.W.; Ng, M.H.; Ho, C.Y.; Cheng, S.H.; Lai, P.B. et al. Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth. Cancer Res. 2011, 71, 4138-4149. [CrossRef] [PubMed]
235. Zhang, B.; Chen, J.; Cheng, A.S.; Ko, B.C. Depletion of sirtuin 1 (SIRT1) leads to epigenetic modifications of telomerase (TERT) gene in hepatocellular carcinoma cells. PLoS ONE 2014, 9, e84931. [CrossRef] [PubMed]
236. Moore, L.D.; Le, T.; Fan, G. DNA methylation and its basic function. Neuropsychopharmacology 2013, 38, 23-38. [CrossRef] [PubMed]
237. Selker, E.U. Gene silencing: Repeats that count. Cell 1999, 97, 157-160. [CrossRef]
238. Devereux, T.R.; Horikawa, I.; Anna, C.H.; Annab, L.A.; Afshari, C.A.; Barrett, J.C. DNA methylation analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene. Cancer Res. 1999, 59, 6087-6090. [PubMed]
239. Iliopoulos, D.; Satra, M.; Drakaki, A.; Poultsides, G.A.; Tsezou, A. Epigenetic regulation of hTERT promoter in hepatocellular carcinomas. Int. J. Oncol. 2009, 34, 391-399. [PubMed]
240. Zinn, R.L.; Pruitt, K.; Eguchi, S.; Baylin, S.B.; Herman, J.G. hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. Cancer Res. 2007, 67, 194-201. [CrossRef] [PubMed]
241. Guilleret, I.; Benhattar, J. Demethylation of the human telomerase catalytic subunit (hTERT) gene promoter reduced hTERT expression and telomerase activity and shortened telomeres. Exp. Cell Res. 2003, 289, 326-334. [CrossRef]
242. Pettigrew, K.A.; Armstrong, R.N.; Colyer, H.A.; Zhang, S.D.; Rea, I.M.; Jones, R.E.; Baird, D.M.; Mills, K.I. Differential TERT promoter methylation and response to 5-Aza-2'-deoxycytidine in acute myeloid leukemia cell lines: TERT expression, telomerase activity, telomere length, and cell death. Genes Chromosomes Cancer 2012, 51, 768-780. [CrossRef] [PubMed]
243. Dessain, S.K.; Yu, H.; Reddel, R.R.; Beijersbergen, R.L.; Weinberg, R.A. Methylation of the human telomerase gene cpg island. Cancer Res. 2000, 60, 537-541. [PubMed]
244. Guilleret, I.; Yan, P.; Grange, F.; Braunschweig, R.; Bosman, F.T.; Benhattar, J. Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity. Int. J. Cancer 2002, 101, 335-341. [CrossRef] [PubMed]
245. Castelo-Branco, P.; Choufani, S.; Mack, S.; Gallagher, D.; Zhang, C.; Lipman, T.; Zhukova, N.; Walker, E.J.; Martin, D.; Merino, D. et al. Methylation of the TERT promoter and risk stratification of childhood brain tumours: An integrative genomic and molecular study. Lancet. Oncol. 2013, 14, 534-542. [CrossRef]
246. Peifer, M.; Hertwig, F.; Roels, F.; Dreidax, D.; Gartlgruber, M.; Menon, R.; Kramer, A.; Roncaioli, J.L.; Sand, F.; Heuckmann, J.M. et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature 2015, 526, 700-704. [CrossRef] [PubMed]
247. Stern, J.L.; Theodorescu, D.; Vogelstein, B.; Papadopoulos, N.; Cech, T.R. Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers. Genes Dev. 2015, 29, 2219-2224. [CrossRef] [PubMed]
248. Ojesina, A.I.; Lichtenstein, L.; Freeman, S.S.; Pedamallu, C.S.; Imaz-Rosshandler, I.; Pugh, T.J.; Cherniack, A.D.; Ambrogio, L.; Cibulskis, K.; Bertelsen, B. et al. Landscape of genomic alterations in cervical carcinomas. Nature 2014, 506, 371-375. [CrossRef] [PubMed]
249. Kandoth, C.; McLellan, M.D.; Vandin, F.; Ye, K.; Niu, B.; Lu, C.; Xie, M.; Zhang, Q.; McMichael, J.F.; Wyczalkowski, M.A. et al. Mutational landscape and significance across 12 major cancer types. Nature 2013, 502, 333-339. [CrossRef] [PubMed]
250. Weinhold, N.; Jacobsen, A.; Schultz, N.; Sander, C.; Lee, W. Genome-wide analysis of noncoding regulatory mutations in cancer. Nat. Genet. 2014, 46, 1160-1165. [CrossRef] [PubMed]
251. Huang, F.W.; Hodis, E.; Xu, M.J.; Kryukov, G.V.; Chin, L.; Garraway, L.A. Highly recurrent TERT promoter mutations in human melanoma. Science 2013, 339, 957-959. [CrossRef] [PubMed]
252. Horn, S.; Figl, A.; Rachakonda, P.S.; Fischer, C.; Sucker, A.; Gast, A.; Kadel, S.; Moll, I.; Nagore, E.; Hemminki, K. et al. Tert promoter mutations in familial and sporadic melanoma. Science 2013, 339, 959-961. [CrossRef] [PubMed]
253. Killela, P.J.; Reitman, Z.J.; Jiao, Y.; Bettegowda, C.; Agrawal, N.; Diaz, L.A., Jr.; Friedman, A.H.; Friedman, H.; Gallia, G.L.; Giovanella, B.C. et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc. Natl. Acad. Sci. USA 2013, 110, 6021-6026. [CrossRef] [PubMed]
254. Quaas, A.; Oldopp, T.; Tharun, L.; Klingenfeld, C.; Krech, T.; Sauter, G.; Grob, T.J. Frequency of TERT promoter mutations in primary tumors of the liver. Virchows Arch. 2014, 465, 673-677. [CrossRef] [PubMed]
255. Kinde, I.; Munari, E.; Faraj, S.F.; Hruban, R.H.; Schoenberg, M.; Bivalacqua, T.; Allaf, M.; Springer, S.; Wang, Y.; Diaz, L.A., Jr. et al. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res. 2013, 73, 7162-7167. [CrossRef] [PubMed]
256. Griewank, K.G.; Schilling, B.; Murali, R.; Bielefeld, N.; Schwamborn, M.; Sucker, A.; Zimmer, L.; Hillen, U.; Schaller, J.; Brenn, T. et al. TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas. Mod. Pathol. 2014, 27, 502-508. [CrossRef] [PubMed]
257. Adeberg, S.; Bernhardt, D.; Harrabi, S.B.; Diehl, C.; Koelsche, C.; Rieken, S.; Unterberg, A.; von Deimling, A.; Debus, J. Radiotherapy plus concomitant temozolomide in primary gliosarcoma. J. Neurooncol. 2016, 128, 341-348. [CrossRef] [PubMed]
258. Oh, J.E.; Ohta, T.; Nonoguchi, N.; Satomi, K.; Capper, D.; Pierscianek, D.; Sure, U.; Vital, A.; Paulus, W.; Mittelbronn, M. et al. Genetic alterations in gliosarcoma and giant cell glioblastoma. Brain Pathol. 2015. [CrossRef] [PubMed]
259. Koelsche, C.; Sahm, F.; Capper, D.; Reuss, D.; Sturm, D.; Jones, D.T.; Kool, M.; Northcott, P.A.; Wiestler, B.; Bohmer, K. et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol. 2013, 126, 907-915. [CrossRef] [PubMed]
260. Huang, D.S.; Wang, Z.; He, X.J.; Diplas, B.H.; Yang, R.; Killela, P.J.; Meng, Q.; Ye, Z.Y.; Wang, W.; Jiang, X.T. et al. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. Eur. J. Cancer 2015, 51, 969-976. [CrossRef] [PubMed]
261. Koelsche, C.; Renner, M.; Hartmann, W.; Brandt, R.; Lehner, B.; Waldburger, N.; Alldinger, I.; Schmitt, T.; Egerer, G.; Penzel, R. et al. TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities. J. Exp. Clin. Cancer Res. 2014. [CrossRef] [PubMed]
262. Vail, E.; Zheng, X.; Zhou, M.; Yang, X.; Fallon, J.T.; Epstein, J.I.; Zhong, M. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder. Ann. Diagn. Pathol. 2015, 19, 301-305. [CrossRef] [PubMed]
263. Nonoguchi, N.; Ohta, T.; Oh, J.E.; Kim, Y.H.; Kleihues, P.; Ohgaki, H. TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol. 2013, 126, 931-937. [CrossRef] [PubMed]
264. Arita, H.; Narita, Y.; Fukushima, S.; Tateishi, K.; Matsushita, Y.; Yoshida, A.; Miyakita, Y.; Ohno, M.; Collins, V.P.; Kawahara, N. et al. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol. 2013, 126, 267-276. [CrossRef] [PubMed]
265. Mosrati, M.A.; Malmstrom, A.; Lysiak, M.; Krysztofiak, A.; Hallbeck, M.; Milos, P.; Hallbeck, A.L.; Bratthall, C.; Strandeus, M.; Stenmark-Askmalm, M. et al. TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma. Oncotarget 2015, 6, 16663-16673. [CrossRef] [PubMed]
266. Simon, M.; Hosen, I.; Gousias, K.; Rachakonda, S.; Heidenreich, B.; Gessi, M.; Schramm, J.; Hemminki, K.; Waha, A.; Kumar, R. TERT promoter mutations: A novel independent prognostic factor in primary glioblastomas. Neuro-Oncology 2015, 17, 45-52. [CrossRef] [PubMed]
267. Labussiere, M.; Boisselier, B.; Mokhtari, K.; Di Stefano, A.L.; Rahimian, A.; Rossetto, M.; Ciccarino, P.; Saulnier, O.; Paterra, R.; Marie, Y. et al. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology 2014, 83, 1200-1206. [CrossRef] [PubMed]
268. Heidenreich, B.; Rachakonda, P.S.; Hosen, I.; Volz, F.; Hemminki, K.; Weyerbrock, A.; Kumar, R. TERT promoter mutations and telomere length in adult malignant gliomas and recurrences. Oncotarget 2015, 6, 10617-10633. [CrossRef] [PubMed]
269. Liu, X.; Wu, G.; Shan, Y.; Hartmann, C.; von Deimling, A.; Xing, M. Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle 2013, 12, 1637-1638. [CrossRef] [PubMed]
270. Vinagre, J.; Almeida, A.; Populo, H.; Batista, R.; Lyra, J.; Pinto, V.; Coelho, R.; Celestino, R.; Prazeres, H.; Lima, L. et al. Frequency of TERT promoter mutations in human cancers. Nat. Commun. 2013. [CrossRef] [PubMed]
271. Fredriksson, N.J.; Ny, L.; Nilsson, J.A.; Larsson, E. Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. Nat. Genet. 2014, 46, 1258-1263. [CrossRef] [PubMed]
272. Batista, R.; Cruvinel-Carloni, A.; Vinagre, J.; Peixoto, J.; Catarino, T.A.; Campanella, N.C.; Menezes, W.; Becker, A.P.; de Almeida, G.C.; Matsushita, M.M. et al. The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism. Int. J. Cancer 2016, 139, 414-423. [CrossRef] [PubMed]
273. Nencha, U.; Rahimian, A.; Giry, M.; Sechi, A.; Mokhtari, K.; Polivka, M.; Schmitt, Y.; Di Stefano, A.L.; Alentorn, A.; Labussiere, M. et al. TERT promoter mutations and rs2853669 polymorphism: Prognostic impact and interactions with common alterations in glioblastomas. J. Neurooncol. 2016, 126, 441-446. [CrossRef] [PubMed]
274. Spiegl-Kreinecker, S.; Lotsch, D.; Ghanim, B.; Pirker, C.; Mohr, T.; Laaber, M.; Weis, S.; Olschowski, A.; Webersinke, G.; Pichler, J. et al. Prognostic quality of activating TERT promoter mutations in glioblastoma: Interaction with the rs2853669 polymorphism and patient age at diagnosis. Neuro-Oncology 2015, 17, 1231-1240. [CrossRef] [PubMed]
275. Brennan, C.W.; Verhaak, R.G.; McKenna, A.; Campos, B.; Noushmehr, H.; Salama, S.R.; Zheng, S.; Chakravarty, D.; Sanborn, J.Z.; Berman, S.H. et al. The somatic genomic landscape of glioblastoma. Cell 2013, 155, 462-477. [CrossRef] [PubMed]
276. Killela, P.J.; Pirozzi, C.J.; Healy, P.; Reitman, Z.J.; Lipp, E.; Rasheed, B.A.; Yang, R.; Diplas, B.H.; Wang, Z.; Greer, P.K. et al. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 2014, 5, 1515-1525. [CrossRef] [PubMed]
277. Gao, K.; Li, G.; Qu, Y.; Wang, M.; Cui, B.; Ji, M.; Shi, B.; Hou, P. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas. Oncotarget 2016, 7, 8712-8725. [PubMed]
278. Labussiere, M.; Di Stefano, A.L.; Gleize, V.; Boisselier, B.; Giry, M.; Mangesius, S.; Bruno, A.; Paterra, R.; Marie, Y.; Rahimian, A. et al. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. Br. J. Cancer 2014, 111, 2024-2032. [CrossRef] [PubMed]
279. Griewank, K.G.; Murali, R.; Puig-Butille, J.A.; Schilling, B.; Livingstone, E.; Potrony, M.; Carrera, C.; Schimming, T.; Moller, I.; Schwamborn, M. et al. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. J. Natl. Cancer Inst. 2014. [CrossRef] [PubMed]
280. Rachakonda, P.S.; Hosen, I.; de Verdier, P.J.; Fallah, M.; Heidenreich, B.; Ryk, C.; Wiklund, N.P.; Steineck, G.; Schadendorf, D.; Hemminki, K. et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc. Natl. Acad. Sci. USA 2013, 110, 17426-17431. [CrossRef] [PubMed]
281. Hurst, C.D.; Platt, F.M.; Knowles, M.A. Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur. Urol. 2014, 65, 367-369. [CrossRef] [PubMed]
282. Allory, Y.; Beukers, W.; Sagrera, A.; Flandez, M.; Marques, M.; Marquez, M.; van der Keur, K.A.; Dyrskjot, L.; Lurkin, I.; Vermeij, M. et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: High frequency across stages, detection in urine, and lack of association with outcome. Eur. Urol. 2014, 65, 360-366. [CrossRef] [PubMed]
283. Wang, K.; Liu, T.; Liu, C.; Meng, Y.; Yuan, X.; Liu, L.; Ge, N.; Liu, J.; Wang, C.; Ren, H. et al. TERT promoter mutations and TERT mrna but not FGFR3 mutations are urinary biomarkers in han chinese patients with urothelial bladder cancer. Oncologist 2015, 20, 263-269. [CrossRef] [PubMed]
284. Yuan, X.; Liu, C.; Wang, K.; Liu, L.; Liu, T.; Ge, N.; Kong, F.; Yang, L.; Bjorkholm, M.; Fan, Y. et al. The genetic difference between western and chinese urothelial cell carcinomas: Infrequent FGFR3 mutation in han chinese patients. Oncotarget 2016. [CrossRef] [PubMed]
285. Wu, S.; Huang, P.; Li, C.; Huang, Y.; Li, X.; Wang, Y.; Chen, C.; Lv, Z.; Tang, A.; Sun, X. et al. Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: A genomic and molecular study. Eur. Urol. 2014, 65, 274-277. [CrossRef] [PubMed]
286. Kurtis, B.; Zhuge, J.; Ojaimi, C.; Ye, F.; Cai, D.; Zhang, D.; Fallon, J.T.; Zhong, M. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications. Ann. Diagn. Pathol. 2016, 21, 7-11. [CrossRef] [PubMed]
287. Cheng, L.; Davidson, D.D.; Wang, M.; Lopez-Beltran, A.; Montironi, R.; Wang, L.; Tan, P.H.; MacLennan, G.T.; Williamson, S.R.; Zhang, S. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change. Histopathology 2015, 69, 107-113. [CrossRef] [PubMed]
288. Borah, S.; Xi, L.; Zaug, A.J.; Powell, N.M.; Dancik, G.M.; Cohen, S.B.; Costello, J.C.; Theodorescu, D.; Cech, T.R. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science 2015, 347, 1006-1010. [CrossRef] [PubMed]
289. Zhong, M.; Tian, W.; Zhuge, J.; Zheng, X.; Huang, T.; Cai, D.; Zhang, D.; Yang, X.J.; Argani, P.; Fallon, J.T. et al. Distinguishing nested variants of urothelial carcinoma from benign mimickers by TERT promoter mutation. Am. J. Surg. Pathol. 2015, 39, 127-131. [CrossRef] [PubMed]
290. Scott, G.A.; Laughlin, T.S.; Rothberg, P.G. Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma. Mod. Pathol. 2014, 27, 516-523. [CrossRef] [PubMed]
291. Griewank, K.G.; Murali, R.; Schilling, B.; Schimming, T.; Moller, I.; Moll, I.; Schwamborn, M.; Sucker, A.; Zimmer, L.; Schadendorf, D. et al. TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma. PLoS ONE 2013, 8, e80354. [CrossRef] [PubMed]
292. Populo, H.; Boaventura, P.; Vinagre, J.; Batista, R.; Mendes, A.; Caldas, R.; Pardal, J.; Azevedo, F.; Honavar, M.; Guimaraes, I. et al. TERT promoter mutations in skin cancer: The effects of sun exposure and x-irradiation. J. Investig. Dermatol. 2014, 134, 2251-2257. [CrossRef] [PubMed]
293. Lin, S.Y.; Liao, S.L.; Hong, J.B.; Chu, C.Y.; Sheen, Y.S.; Jhuang, J.Y.; Tsai, J.H.; Liau, J.Y. TERT promoter mutations in periocular carcinomas: Implications of ultraviolet light in pathogenesis. Br. J. Ophthalmol. 2016, 100, 274-277. [CrossRef] [PubMed]
294. Cheng, K.A.; Kurtis, B.; Babayeva, S.; Zhuge, J.; Tantchou, I.; Cai, D.; Lafaro, R.J.; Fallon, J.T.; Zhong, M. Heterogeneity of TERT promoter mutations status in squamous cell carcinomas of different anatomical sites. Ann. Diagn. Pathol. 2015, 19, 146-148. [CrossRef] [PubMed]
295. Liu, J.; Zhao, Z.; Sun, M.; Chen, K.; Yuan, W.; Jiang, G. The sensitive detection of telomerase reverse transcriptase promoter mutation by amplification refractory mutation system-PCR. Genet. Test. Mol. Biomark. 2016, 20, 90-93. [CrossRef] [PubMed]
296. Liu, X.; Bishop, J.; Shan, Y.; Pai, S.; Liu, D.; Murugan, A.K.; Sun, H.; El-Naggar, A.K.; Xing, M. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr. Relat. Cancer 2013, 20, 603-610. [CrossRef] [PubMed]
297. Landa, I.; Ganly, I.; Chan, T.A.; Mitsutake, N.; Matsuse, M.; Ibrahimpasic, T.; Ghossein, R.A.; Fagin, J.A. Frequent somatic TERT promoter mutations in thyroid cancer: Higher prevalence in advanced forms of the disease. J. Clin. Endocrinol. Metab. 2013, 98, E1562-E1566. [CrossRef] [PubMed]
298. Shi, X.; Liu, R.; Qu, S.; Zhu, G.; Bishop, J.; Liu, X.; Sun, H.; Shan, Z.; Wang, E.; Luo, Y. et al. Association of TERT promoter mutation 1, 295, 228 c>t with braf v600e mutation, older patient age, and distant metastasis in anaplastic thyroid cancer. J. Clin. Endocrinol. Metab. 2015, 100, E632-E637. [CrossRef] [PubMed]
299. Melo, M.; da Rocha, A.G.; Vinagre, J.; Batista, R.; Peixoto, J.; Tavares, C.; Celestino, R.; Almeida, A.; Salgado, C.; Eloy, C. et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J. Clin. Endocrinol. Metab. 2014, 99, E754-E765. [CrossRef] [PubMed]
300. Liu, T.; Wang, N.; Cao, J.; Sofiadis, A.; Dinets, A.; Zedenius, J.; Larsson, C.; Xu, D. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene 2014, 33, 4978-4984. [CrossRef] [PubMed]
301. Landa, I.; Ibrahimpasic, T.; Boucai, L.; Sinha, R.; Knauf, J.A.; Shah, R.H.; Dogan, S.; Ricarte-Filho, J.C.; Krishnamoorthy, G.P.; Xu, B. et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J. Clin. Investig. 2016, 126, 1052-1066. [CrossRef] [PubMed]
302. Wang, K.; Liu, T.; Ge, N.; Liu, L.; Yuan, X.; Liu, J.; Kong, F.; Wang, C.; Ren, H.; Yan, K. et al. TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castpcr. Oncotarget 2014, 5, 12428-12439. [CrossRef] [PubMed]
303. Nault, J.C.; Mallet, M.; Pilati, C.; Calderaro, J.; Bioulac-Sage, P.; Laurent, C.; Laurent, A.; Cherqui, D.; Balabaud, C.; Zucman-Rossi, J. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat. Commun. 2013. [CrossRef]
304. Cevik, D.; Yildiz, G.; Ozturk, M. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations. World J. Gastroenterol. 2015, 21, 311-317. [CrossRef] [PubMed]
305. Chen, Y.L.; Jeng, Y.M.; Chang, C.N.; Lee, H.J.; Hsu, H.C.; Lai, P.L.; Yuan, R.H. TERT promoter mutation in resectable hepatocellular carcinomas: A strong association with hepatitis c infection and absence of hepatitis b infection. Int. J. Surg. 2014, 12, 659-665. [CrossRef] [PubMed]
306. Yang, X.; Guo, X.; Chen, Y.; Chen, G.; Ma, Y.; Huang, K.; Zhang, Y.; Zhao, Q.; Winkler, C.A.; An, P. et al. Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma. Oncotarget 2016. [CrossRef] [PubMed]
307. Totoki, Y.; Tatsuno, K.; Covington, K.R.; Ueda, H.; Creighton, C.J.; Kato, M.; Tsuji, S.; Donehower, L.A.; Slagle, B.L.; Nakamura, H. et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat. Genet. 2014, 46, 1267-1273. [CrossRef] [PubMed]
308. de Unamuno Bustos, B.; Murria Estal, R.; Perez Simo, G.; Oliver Martinez, V.; Llavador Ros, M.; Palanca Suela, S.; Botella Estrada, R. Lack of TERT promoter mutations in melanomas with extensive regression. J. Am. Acad. Dermatol. 2016, 74, 570-572. [CrossRef] [PubMed]
309. Egberts, F.; Kruger, S.; Behrens, H.M.; Bergner, I.; Papaspyrou, G.; Werner, J.A.; Alkatout, I.; Haag, J.; Hauschild, A.; Rocken, C. Melanomas of unknown primary frequently harbor TERT-promoter mutations. Melanoma Res. 2014, 24, 131-136. [CrossRef] [PubMed]
310. Chan, A.K.; Yao, Y.; Zhang, Z.; Chung, N.Y.; Liu, J.S.; Li, K.K.; Shi, Z.; Chan, D.T.; Poon, W.S.; Zhou, L. et al. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. Mod. Pathol. 2015, 28, 177-186. [CrossRef] [PubMed]
311. Koopmans, A.E.; Ober, K.; Dubbink, H.J.; Paridaens, D.; Naus, N.C.; Belunek, S.; Krist, B.; Post, E.; Zwarthoff, E.C.; de Klein, A. et al. Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions. Investig. Ophthalmol. Vis. Sci. 2014, 55, 6024-6030. [CrossRef] [PubMed]
312. Griewank, K.G.; Murali, R.; Schilling, B.; Scholz, S.; Sucker, A.; Song, M.; Susskind, D.; Grabellus, F.; Zimmer, L.; Hillen, U. et al. TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br. J. Cancer 2013, 109, 497-501. [CrossRef] [PubMed]
313. Heidenreich, B.; Nagore, E.; Rachakonda, P.S.; Garcia-Casado, Z.; Requena, C.; Traves, V.; Becker, J.; Soufir, N.; Hemminki, K.; Kumar, R. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. Nat. Commun. 2014. [CrossRef] [PubMed]
314. Macerola, E.; Loggini, B.; Giannini, R.; Garavello, G.; Giordano, M.; Proietti, A.; Niccoli, C.; Basolo, F.; Fontanini, G. Coexistence of TERT promoter and braf mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness. Virchows Arch. 2015, 467, 177-184. [CrossRef] [PubMed]
315. Qasem, E.; Murugan, A.K.; Al-Hindi, H.; Xing, M.; Almohanna, M.; Alswailem, M.; Alzahrani, A.S. TERT promoter mutations in thyroid cancer: A report from a middle eastern population. Endocr. Relat. Cancer 2015, 22, 901-908. [CrossRef] [PubMed]
316. Remke, M.; Ramaswamy, V.; Peacock, J.; Shih, D.J.; Koelsche, C.; Northcott, P.A.; Hill, N.; Cavalli, F.M.; Kool, M.; Wang, X. et al. TERT promoter mutations are highly recurrent in shh subgroup medulloblastoma. Acta Neuropathol. 2013, 126, 917-929. [CrossRef] [PubMed]
317. Lindsey, J.C.; Schwalbe, E.C.; Potluri, S.; Bailey, S.; Williamson, D.; Clifford, S.C. TERT promoter mutation and aberrant hypermethylation are associated with elevated expression in medulloblastoma and characterise the majority of non-infant shh subgroup tumours. Acta Neuropathol. 2014, 127, 307-309. [CrossRef] [PubMed]
318. Ohta, T.; Kim, Y.H.; Oh, J.E.; Satomi, K.; Nonoguchi, N.; Keyvani, K.; Pierscianek, D.; Sure, U.; Mittelbronn, M.; Paulus, W. et al. Alterations of the RRAS and ERCC1 genes at 19q13 in gemistocytic astrocytomas. J. Neuropathol. Exp. Neurol. 2014, 73, 908-915. [CrossRef] [PubMed]
319. Bruno, A.; Alentorn, A.; Daniau, M.; Labussiere, M.; Rahimian, A.; Tabouret, E.; Polivka, M.; Jouvet, A.; Adam, C.; Figarella-Branger, D. et al. TERT promoter mutations in primary central nervous system lymphoma are associated with spatial distribution in the splenium. Acta Neuropathol. 2015, 130, 439-440. [CrossRef] [PubMed]
320. Muzza, M.; Colombo, C.; Rossi, S.; Tosi, D.; Cirello, V.; Perrino, M.; De Leo, S.; Magnani, E.; Pignatti, E.; Vigo, B. et al. Telomerase in differentiated thyroid cancer: Promoter mutations, expression and localization. Mol. Cell. Endocrinol. 2015, 399, 288-295. [CrossRef] [PubMed]
321. Wang, N.; Liu, T.; Sofiadis, A.; Juhlin, C.C.; Zedenius, J.; Hoog, A.; Larsson, C.; Xu, D. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. Cancer 2014, 120, 2965-2979. [CrossRef] [PubMed]
322. Song, Y.S.; Lim, J.A.; Choi, H.; Won, J.K.; Moon, J.H.; Cho, S.W.; Lee, K.E.; Park, Y.J.; Yi, K.H.; Park do, J. et al. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients. Cancer 2016, 122, 1370-1379. [CrossRef] [PubMed]
323. Bae, J.S.; Kim, Y.; Jeon, S.; Kim, S.H.; Kim, T.J.; Lee, S.; Kim, M.H.; Lim, D.J.; Lee, Y.S.; Jung, C.K. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation. Diagn. Pathol. 2016. [CrossRef] [PubMed]
324. Huang, H.N.; Chiang, Y.C.; Cheng, W.F.; Chen, C.A.; Lin, M.C.; Kuo, K.T. Molecular alterations in endometrial and ovarian clear cell carcinomas: Clinical impacts of telomerase reverse transcriptase promoter mutation. Mod. Pathol. 2015, 28, 303-311. [CrossRef] [PubMed]
325. Wu, R.C.; Ayhan, A.; Maeda, D.; Kim, K.R.; Clarke, B.A.; Shaw, P.; Chui, M.H.; Rosen, B.; Shih Ie, M.; Wang, T.L. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. J. Pathol. 2014, 232, 473-481. [CrossRef] [PubMed]
326. Chindris, A.M.; Casler, J.D.; Bernet, V.J.; Rivera, M.; Thomas, C.; Kachergus, J.M.; Necela, B.M.; Hay, I.D.; Westphal, S.A.; Grant, C.S. et al. Clinical and molecular features of hurthle cell carcinoma of the thyroid. J. Clin. Endocrinol. Metab. 2015, 100, 55-62. [CrossRef] [PubMed]
327. Tallet, A.; Nault, J.C.; Renier, A.; Hysi, I.; Galateau-Salle, F.; Cazes, A.; Copin, M.C.; Hofman, P.; Andujar, P.; Le Pimpec-Barthes, F. et al. Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. Oncogene 2014, 33, 3748-3752. [CrossRef] [PubMed]
328. Akaike, K.; Kurisaki-Arakawa, A.; Hara, K.; Suehara, Y.; Takagi, T.; Mitani, K.; Kaneko, K.; Yao, T.; Saito, T. Distinct clinicopathological features of NAB2-STAT6 fusion gene variants in solitary fibrous tumor with emphasis on the acquisition of highly malignant potential. Hum. Pathol. 2015, 46, 347-356. [CrossRef] [PubMed]
329. Liau, J.Y.; Tsai, J.H.; Jeng, Y.M.; Chu, C.Y.; Kuo, K.T.; Liang, C.W. TERT promoter mutation is uncommon in acral lentiginous melanoma. J. Cutan. Pathol. 2014, 41, 504-508. [CrossRef] [PubMed]
330. George, J.R.; Henderson, Y.C.; Williams, M.D.; Roberts, D.B.; Hei, H.; Lai, S.Y.; Clayman, G.L. Association of TERT promoter mutation, but not BRAF mutation, with increased mortality in PTC. J. Clin. Endocrinol. Metab. 2015, 100, E1550-E1559. [CrossRef] [PubMed]
331. Xing, M.; Liu, R.; Liu, X.; Murugan, A.K.; Zhu, G.; Zeiger, M.A.; Pai, S.; Bishop, J. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J. Clin. Oncol. 2014, 32, 2718-2726. [CrossRef] [PubMed]
332. Liu, R.; Xing, M. Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy. Endocr. Relat. Cancer 2014, 21, 825-830. [CrossRef] [PubMed]
333. Liu, X.; Qu, S.; Liu, R.; Sheng, C.; Shi, X.; Zhu, G.; Murugan, A.K.; Guan, H.; Yu, H.; Wang, Y. et al. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J. Clin. Endocrinol. Metab. 2014, 99, E1130-E1136. [CrossRef] [PubMed]
334. Dettmer, M.S.; Schmitt, A.; Steinert, H.; Capper, D.; Moch, H.; Komminoth, P.; Perren, A. Tall cell papillary thyroid carcinoma: New diagnostic criteria and mutations in braf and TERT. Endocr. Relat. Cancer 2015, 22, 419-429. [CrossRef] [PubMed]
335. Jin, L.; Chen, E.; Dong, S.; Cai, Y.; Zhang, X.; Zhou, Y.; Zeng, R.; Yang, F.; Pan, C.; Liu, Y. et al. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: A study of 653 patients. Oncotarget 2016, 7, 18346-18355. [CrossRef] [PubMed]
336. Myung, J.K.; Kwak, B.K.; Lim, J.A.; Lee, M.C.; Kim, M.J. TERT Promoter mutations and tumor persistence/recurrence in papillary thyroid cancer. Cancer Res. Treat. 2016, 48, 942-947. [CrossRef] [PubMed]
337. Jeon, M.J.; Kim, W.G.; Sim, S.; Lim, S.; Kwon, H.; Kim, T.Y.; Shong, Y.K.; Kim, W.B. Low prevalence of somatic TERT promoter mutations in classic papillary thyroid carcinoma. Endocrinol. Metab. 2016, 31, 100-104. [CrossRef] [PubMed]
338. Bullock, M.; Ren, Y.; O'Neill, C.; Gill, A.; Aniss, A.; Sywak, M.; Sidhu, S.; Delbridge, L.; Learoyd, D.; de Vathaire, F. et al. TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas. Clin. Endocrinol. 2016, 85, 283-190. [CrossRef] [PubMed]
339. Qu, Y.; Shi, L.; Wang, D.; Zhang, B.; Yang, Q.; Ji, M.; Shi, B.; Hou, P. Low frequency of TERT promoter mutations in a large cohort of gallbladder and gastric cancers. Int. J. Cancer 2014, 134, 2993-2994. [CrossRef] [PubMed]
340. Papathomas, T.G.; Oudijk, L.; Zwarthoff, E.C.; Post, E.; Duijkers, F.A.; van Noesel, M.M.; Hofland, L.J.; Pollard, P.J.; Maher, E.R.; Restuccia, D.F. et al. Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia. Endocr. Relat. Cancer 2014, 21, 653-661. [CrossRef] [PubMed]
341. Liu, T.; Brown, T.C.; Juhlin, C.C.; Andreasson, A.; Wang, N.; Backdahl, M.; Healy, J.M.; Prasad, M.L.; Korah, R.; Carling, T. et al. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors. Endocr. Relat. Cancer 2014, 21, 427-434. [CrossRef] [PubMed]
342. Wang, K.; Liu, T.; Liu, L.; Liu, J.; Liu, C.; Wang, C.; Ge, N.; Ren, H.; Yan, K.; Hu, S. et al. TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas. Oncotarget 2014, 5, 1829-1836. [CrossRef] [PubMed]
343. Jangard, M.; Zebary, A.; Ragnarsson-Olding, B.; Hansson, J. TERT promoter mutations in sinonasal malignant melanoma: A study of 49 cases. Melanoma Res. 2015, 25, 185-188. [CrossRef] [PubMed]
344. Lee, S.; Barnhill, R.L.; Dummer, R.; Dalton, J.; Wu, J.; Pappo, A.; Bahrami, A. TERT promoter mutations are predictive of aggressive clinical behavior in patients with spitzoid melanocytic neoplasms. Sci. Rep. 2015. [CrossRef] [PubMed]
345. Goutagny, S.; Nault, J.C.; Mallet, M.; Henin, D.; Rossi, J.Z.; Kalamarides, M. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol. 2014, 24, 184-189. [CrossRef] [PubMed]
346. Sahm, F.; Schrimpf, D.; Olar, A.; Koelsche, C.; Reuss, D.; Bissel, J.; Kratz, A.; Capper, D.; Schefzyk, S.; Hielscher, T. et al. TERT promoter mutations and risk of recurrence in meningioma. J. Natl. Cancer Inst. 2016. [CrossRef]
347. Carcano, F.M.; Vidal, D.O.; van Helvoort Lengert, A.; Neto, C.S.; Queiroz, L.; Marques, H.; Baltazar, F.; da Silva Martinelli, C.M.; Soares, P.; da Silva, E.C. et al. Hotspot TERT promoter mutations are rare events in testicular germ cell tumors. Tumour Biol. 2016, 37, 4901-4907. [CrossRef]
348. Campanella, N.C.; Celestino, R.; Pestana, A.; Scapulatempo-Neto, C.; de Oliveira, A.T.; Brito, M.J.; Gouveia, A.; Lopes, J.M.; Guimaraes, D.P.; Soares, P. et al. Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs). Eur. J. Hum. Genet. 2015, 23, 877-879. [CrossRef] [PubMed]
349. Akaike, K.; Toda-Ishii, M.; Suehara, Y.; Mukaihara, K.; Kubota, D.; Mitani, K.; Takagi, T.; Kaneko, K.; Yao, T.; Saito, T. TERT promoter mutations are a rare event in gastrointestinal stromal tumors. Springerplus 2015. [CrossRef] [PubMed]
350. Zhao, Y.; Gao, Y.; Chen, Z.; Hu, X.; Zhou, F.; He, J. Low frequency of TERT promoter somatic mutation in 313 sporadic esophageal squamous cell carcinomas. Int. J. Cancer 2014, 134, 493-494. [CrossRef]
351. Dono, M.; Angelini, G.; Cecconi, M.; Amaro, A.; Esposito, A.I.; Mirisola, V.; Maric, I.; Lanza, F.; Nasciuti, F.; Viaggi, S. et al. Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: Detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma. Br. J. Cancer 2014, 110, 1058-1065. [CrossRef] [PubMed]
352. Hosen, I.; Rachakonda, P.S.; Heidenreich, B.; de Verdier, P.J.; Ryk, C.; Steineck, G.; Hemminki, K.; Kumar, R. Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer. Int. J. Cancer 2015, 137, 1621-1629. [CrossRef] [PubMed]
353. Qu, Y.; Dang, S.; Wu, K.; Shao, Y.; Yang, Q.; Ji, M.; Shi, B.; Hou, P. TERT promoter mutations predict worse survival in laryngeal cancer patients. Int. J. Cancer 2014, 135, 1008-1010. [CrossRef] [PubMed]
354. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674. [CrossRef] [PubMed]
355. Ruden, M.; Puri, N. Novel anticancer therapeutics targeting telomerase. Cancer Treat. Rev. 2013, 39, 444-456. [CrossRef] [PubMed]